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ABSTRACT 
Metabolic Regulation is a complex system used to control cellular metabolism in 
response to conditions in the cell’s environment. For most enzymes, the cell can rely upon a 
minimal amount of regulation; however, critical enzymes, such as acetyl-CoA carboxylase, must 
be regulated at multiple levels. Acetyl-CoA carboxylase catalyzes the first committed step in 
fatty acid synthesis. In bacteria, acetyl-CoA carboxylase forms a complex of three subunits–
biotin carboxylase, biotin carboxyl carrier protein, and carboxyltransferase–which catalyze the 
carboxylation of acetyl-CoA to form malonyl-CoA via two half-reactions. In the first half-
reaction, biotin covalently linked to biotin carboxyl carrier protein is carboxylated by biotin 
carboxylase. Carboxyltransferase catalyzes the second half-reaction where the carboxyl group is 
transferred from carboxybiotin to acetyl-CoA, forming malonyl-CoA. As acetyl-CoA 
carboxylase is a critical enzyme in cell growth, it is subject to multiple forms of regulation. This 
dissertation describes two distinct mechanisms of regulation of acetyl-CoA carboxylase. 
Previous reports showed that the downstream product of fatty acid synthesis, palmitoyl-acyl 
carrier protein, inhibits catalysis by acetyl-CoA carboxylase via negative feedback regulation. 
This dissertation reports the acetyl-CoA carboxylase complex was found to exhibit a pronounced 
hysteresis when inhibited by palmitoyl-acyl carrier protein. Alternatively, palmitoyl-acyl carrier 
protein does not inhibit either half–reaction. Structure-function studies of palmitoyl-acyl carrier 
protein demonstrate the inhibitory moiety is the cofactor pantothenic acid. This dissertation also 
reports that the biotin carboxyl carrier protein subunit of acetyl-CoA carboxylase regulates 
catalysis. The biotin carboxyl carrier protein in E. coli is composed of two domains: the N-
terminal domain, and the C-terminal domain. The C-terminal domain contains the biotin 
cofactor, and acts as a substrate, while the function of the N-terminal domain was unknown. In 
  x 
vivo pull-down assays demonstrated the N-terminal domain is not required for formation of the 
catalytic complex, whereas in vitro analyses demonstrated that the N-terminal domain binds 
biotin. Thus, it is likely the role of the N-terminal domain of biotin carboxyl carrier protein in 
bacterial acetyl-CoA carboxylase is to bind and stabilize the carboxybiotin intermediate during 
catalysis.  
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CHAPTER 1. INTRODUCTION 
 
1.1 Bacterial Metabolic Regulation 
 
1.1.1 Background 
 
Research into metabolic pathways has roots as early as the 17th century [1]; however, the 
modern concept of metabolism first appeared in the mid-19th century when Pasteur began 
research into fermentation [2, 3]. The concept of metabolism was further advanced by the 
discovery of enzymes by Eduard Buchner in the mid-20th century. The work of both Pasteur and 
Buchner laid the groundwork for the revelation that enzymes do not act independently, but 
instead are part of a complicated metabolic network [4]. The activity of the enzymes in the 
metabolic network are regulated in response to changes in the cellular environment. 
In bacteria, there are four main types of regulation to maintain homeostasis in the cell [3]. 
The first two types of regulation are transcriptional and translational, which are used to control 
protein production at the genetic level. The third type of regulation is post translational 
modifications (PTMs), which can activate or inactivate an enzyme. The fourth most common 
type of metabolic regulation is enzyme-metabolite interactions, i.e. negative or positive feedback 
or feed-forward regulation. Examples of each of these types of regulation are given below. 
1.1.2 Transcriptional Regulation 
The most influential report on transcriptional regulation was the study of the lac operon 
in E. coli by Jacob and Monod [5]. Jacob and Monod determined the lac operon is regulated 
positively by lactose and negatively by glucose. Glucose is the primary energy source required 
for metabolism; however, in the absence of glucose bacterial cells can metabolize lactose for 
energy. In order to use lactose, the cell must first transcribe the genes coding for the enzymes 
that metabolize lactose, which are encoded on the lac operon. (Figure 1.1, Purple, Yellow, and 
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Red). In the absence of lactose, a repressor binds the operator (Figure 1.1, Grey) preventing 
RNA polymerase from binding the promoter region (Figure 1.1 labelled), and by inference from 
transcribing of the genes. However, when lactose is present an isomer of lactose (allolactose) 
binds the repressor to cause a conformational change. The repressor is then forced to release the 
operator allowing RNA polymerase to bind and transcribe the genes. Expression of the lac 
operon is increased when glucose levels are low. In the absence of glucose, cyclic AMP (cAMP) 
concentrations increase allowing cAMP to bind the catabolite activator protein (CAP). This 
causes a conformational change in CAP allowing the protein to bind the CAP site (Figure 1.1, 
Green). Binding of CAP to the CAP site increases transcription rates for the lac operon [5]. 
Alternatively, in the presence of glucose, there is a low concentration of cAMP, meaning less 
activated CAP to bind the CAP site. Though the lac operon can still be transcribed in the absence 
of the activator, it is at a slower rate.  
 
Figure 1.1. Schematic of the lac Operon. The cap binding site (green), the leader region (blue), 
and the operator (grey) are labelled. The catalytic enzymes the genes code for are in purple, 
yellow and red. The promoter (black) is composed of both the leader region (blue) and part of the 
operator (grey). 
 
Similar to the lac operon, the trp operon relies on transcriptional regulation to control the 
expression of the genes it encodes. The trp operon contains genes for the proteins required for 
tryptophan biosynthesis (Figure 1.2, Navy, Red, Green, Brown, and Pink), and is regulated in 
two ways: via a repressor and attenuation [6]. 
When tryptophan levels are high, tryptophan binds a repressor causing a conformational 
change which allows the repressor to bind the operator (Figure 1.2, Light Pink). This blocks 
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RNA polymerase from binding (and, therefore, from transcribing) the operon. Alternatively, 
when tryptophan levels decrease, tryptophan will release the repressor, causing the repressor to 
detach from the operon, allowing the genes to be transcribed. [6].  
 
Figure 1.2. Schematic of the trp Operon. The promoter (blue), the operator (light pink), and the 
leader region (purple) are labelled. The enzymes for tryptophan biosynthesis coded for by the 
operon are in navy, red, green, brown, and pink, respectively.  
 
The trp operon is also regulated via attenuation. Between the operator and Trp E there is 
a leader region (Figure 1.3) containing four sections. The first section (Figure 1.3, Purple) codes 
for a 14-amino acid polypeptide containing two tryptophans. Sections 2, 3, and 4 (Figure 1.3 
Red, Green, and Pink, respectively) are non-coding regions referred to as attenuator regions. As 
RNA polymerase transcribes the genes, a ribosome binds to the transcript, initializing translation. 
If there is a surplus of tryptophan in the cell, the ribosome is able to translate the leader 
polypeptide (Figure 1.3, Purple). As the ribosome translocates, it covers both regions 1 and 2 of 
the mRNA (Figure 1.3 Purple and Red, respectively). This allows attenuator regions 3 and 4 
(Figure 1.3, Green and Pink, respectively) of the mRNA to base pair forming a hairpin loop, 
which causes RNA polymerase to release the DNA without completing transcription. 
Alternatively, if the concentration of tryptophan is low in the cell, then when the ribosome binds 
the still-forming transcript it will pause on the two codons for tryptophan in region 1 of the 
mRNA (Figure 1.3, Purple). This allows regions 2 and 3 (Figure 1.3 Red and Green, 
respectively) of the mRNA to base pair, forming a hairpin loop that prevents region 3 (Figure 
1.3, Green) from pairing with region 4 (Figure 1.3, Pink). RNA polymerase will then continue 
transcription of the genes for tryptophan biosynthesis [6]. 
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Figure 1.3. Schematic of the trp Operon and the Leader Sequence. The promoter is blue, the 
operator is light pink, the leader region is purple, and the enzymes coded for by the operon are 
navy, red, green, brown, and pink, respectively. The leader region is identified and contains four 
regions: the leader poly peptide region (1, purple) and three attenuator regions (2 (red), 3 (green), 
and 4 (pink)). 
 
Transcriptional control of enzyme production is beneficial, yet this type of regulation 
requires time and energy to adjust to changes in the environment. Thus, the cell employs 
translational regulation in order to respond more quickly 
1.1.3 Translational Regulation 
Most translational control is directed towards initiation because it is the rate-limiting step. 
One example is the negative regulation threonyl-tRNA synthetase (ThrRS) exhibits by binding 
its mRNA [7, 8]. Threonyl-tRNA synthetase is the enzyme in E. coli that charges tRNAThr in an 
ATP-dependent manner. When threonine levels are high, ATP and threonine bind ThrRS, 
inducing a conformational change that causes the enzyme to preferentially bind tRNAthr [9]. 
Alternatively, in the absence of threonine ThrRS preferentially binds its mRNA thereby 
preventing translation. Figure 1.4 is a representation of the initiation and autoregulatory regions 
in the leader region of the mRNA for ThrRS. The leader region of the mRNA for ThrRS is 
composed of four domains. Domain 1 consists of one part of the split ribosome binding site, the 
Shine Dalgarno sequence (Green), and the methionine start codon (Green). The second part of 
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the split ribosome binding site is in domain 3, which also contains a noncoding region of the 
mRNA. Domain 2 and domain 4 contain hairpins (Pink) where free ThrRS binds in the absence 
of threonine. It is important to note that ThrRS recognizes and binds Domains 2 and 4 (Pink) 
because the hairpins mimic the anticodon arm of tRNAthr, (which ThrRS binds when in the 
presence of threonine). The bases that are similar to the anticodon of tRNAthr are in blue. The 
anticodon arm of tRNAthr is shown in black as a reference, with the corresponding bases also in 
blue [10].  
                         
 
Figure 1.4. mNRA for ThrRs in E. coli. The mRNA is organized into four domains. Domain 1 
contains part of the split ribosome binding site (labelled), the Shine Dalgarno sequence (green), 
and the start codon (green). Domain 3 contains the rest of the ribosomal binding site. Domains 2 
and 4 are the hairpins where ThrRS binds. Blue represents the anticodon in the tRNAthr (black) 
and the recognition site for ThrRS of the mRNA hairpins (pink). From Babitzke et al [10]. 
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1.1.4 Post Translational Modifications 
The activity of an enzyme can also be controlled via post translational modifications. Post 
translational modifications (PTMs) are defined as covalent alterations made to an enzyme that 
may change its properties [3]. An example of a PTM in E. coli is the inactivation of isocitrate 
dehydrogenase via phosphorylation. This phosphorylation is carried out by the enzyme isocitrate 
kinase/phosphatase, an enzyme that catalyzes both the phosphorylation and dephosphorylation of 
isocitrate dehydrogenase [11, 12]. Isocitrate dehydrogenase (from the citric acid cycle) 
decarboxylates isocitrate to form α-ketoglutarate and carbon dioxide when glucose is available. 
Alternatively, when glucose is absent, the cell must use the glyoxylate cycle to bypass the 
decarboxylation steps of the TCA cycle to conserve carbons. Thus, in the absence of glucose 
isocitrate dehydrogenase is phosphorylated, and therefore inactivated, causing the concentration 
of the substrate isocitrate to increase. Isocitrate is then diverted to the glyoxylate cycle, where the 
enzyme isocitrate lyase cleaves isocitrate into succinate and glyoxylate. Succinate can then be 
incorporated directly into the TCA cycle while glyoxylate must be converted to malate by malate 
dehydrogenase before being incorporated into the citric acid cycle.  
Like both transcriptional and translational regulation, PTMs are used to maintain 
homeostasis. Though PTMs can be enacted faster than transcriptional or translational regulation, 
these modifications usually require other enzymes and an energy source, such as ATP, to make 
these modification [3]. In contrast, enzymatic activity can also be regulated without the aid of 
other enzymes or an energy source by interacting with metabolites.  
1.1.5 Enzyme Metabolite Interactions 
An example of both positive and negative regulation via enzyme-metabolite interactions 
is the enzyme aspartate transcarbamylase (ATCase), which catalyzes the first committed step in 
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pyrimidine biosynthesis (Figure 1.5) in which carbamoyl phosphate is converted to N-carbamoyl 
aspartate. When ATP is at high concentrations, the purine binds aspartate transcarbamylase 
allosterically to activate the enzyme. This increases the flux through the pathway and, ultimately, 
the production of the downstream product, CTP. Alternatively, at low concentrations of ATP, 
aspartate transcarbamylase will still catalyze the reaction, but at a slower rate [13]. Aspartate 
transcarbamylase is also negatively regulated via feedback inhibition by CTP. When the CTP 
concentration is high, it binds aspartate transcarbamylase allosterically, inhibiting the enzyme, 
and decreasing synthesis of pyrimidines. Once the concentration of CTP decreases this inhibition 
is alleviated [14, 15].  
 
Figure 1.5. Schematic of the Activation and Inhibition of ATCase. The downstream product of 
pyrimidine synthesis, CTP, negatively regulates aspartate transcarbamylase. ATP increases 
activity of aspartate transcarbamylase. 
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Regulation by enzyme-metabolite interactions has three major benefits. First, it is an 
immediate reaction to the cellular environment. Second, this type of inhibition is reversible, as 
once the concentration of regulatory metabolites decreases, they will no longer affect an enzyme. 
Third, a metabolite inhibiting or activating an enzyme requires no unnecessary energy 
expenditure, unlike regulatory mechanisms previously described. 
1.2 Acetyl-CoA Carboxylase 
 
The extent of regulation on an enzyme is dependent upon the role that enzyme plays in 
the network of metabolic regulation [3]. Some enzymes are so critical to cell function that the 
cell must rely upon multiple forms of regulation to control the growth rate of the cell. This 
dissertation focuses on one enzyme that requires several forms of regulation: acetyl-CoA 
carboxylase (ACC), which catalyzes the first committed step in fatty acid synthesis [16]. To 
understand the multiple ways in which ACC is regulated it is important to first understand the 
structure and function of the enzyme. 
1.2.1 Background 
 
Acetyl-CoA carboxylase catalyzes the ATP-dependent carboxylation of acetyl-CoA to 
form malonyl-CoA. In most Gram-negative and Gram-positive organisms, catalysis requires the 
formation of a macromolecular complex composed of three distinct proteins: biotin carboxylase 
(BC), carboxyltransferase (CT), and biotin carboxyl carrier protein (BCCP) [16, 17]. 
Carboxylation of acetyl-CoA by ACC takes place via two half-reactions. In the first half-reaction 
BC catalyzes the carboxylation of biotin, covalently linked to BCCP. In the second half-reaction 
CT catalyzes the transfer of the carboxyl group to acetyl-CoA, forming malonyl-CoA (Scheme 
1.1). Though a complex is required for catalysis of the overall reaction, both BC and CT can be 
isolated and will retain their activity when assayed individually [16, 17].  
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Scheme 1.1. Acetyl-CoA Carboxylase Reaction 
 
1.2.2 Biotin Dependent Enzymes 
Acetyl-CoA carboxylase belongs to a class of enzymes referred to as biotin dependent 
enzymes [18]. These enzymes proceed via two half-reactions and require the cofactor biotin, also 
known as vitamin H or B7 [18].  
1.2.2.1 Structure of Biotin 
The vitamin biotin is a bicyclic compound, composed of an ureido ring, a valeric acid 
side chain, and a tetrahydrothiophene ring (Figure 1.6). The rings are fused in a cis conformation 
with respect to each other, while the valeric acid side chain is cis to the ureido ring. The structure 
of biotin contains three chiral carbons, which gives a possible eight isomers of the vitamin, 
however, only (D)-+- biotin is active in nature (Figure 1.6). 
                                                         
 
Figure 1.6. Structure of (D)-+-Biotin. 
1.2.2.2 Classifications of Biotin Dependent Enzymes 
There are three classes of biotin dependent enzymes in bacteria: class I carboxylases, 
class II decarboxylases, and class III transcarboxylases [18]. Most biotin dependent enzymes are 
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class I, which is defined by both the enzymes’ fixation of carbon dioxide, and a distinct catalytic 
mechanism, which includes a carboxyphosphate intermediate [18]. Acetyl-CoA carboxylase is a 
class I biotin dependent enzyme. The decarboxylases (class II enzymes) catalyze the removal of 
a carbonyl group from a substrate, which is then released as bicarbonate [18]. These enzymes are 
found in anaerobic bacteria and are involved in pumping sodium out of the cell without the use 
of ATP [18]. Currently, there is only one known enzyme in class III, which is methylmalonyl-
CoA oxaloacetate transcarboxylase. This enzyme is involved in the production of propionic acid 
in Propionibacterium shermanii [19]. Transcarboxylase is unique as it does not use or release 
free CO2 [18], i.e., the carbon dioxide group is attached to methylmalonyl-CoA, transferred to the 
biotin on the enzyme, and then transferred to pyruvate to form oxaloacetate. 
1.2.3 Subunits of Acetyl-CoA Carboxylase 
1.2.3.1 Biotin Carboxylase 
1.2.3.1.1 Three-Dimensional Structure of Biotin Carboxylase 
 Biotin carboxylase catalyzes the first half-reaction of ACC (Scheme 1.1). The crystal 
structure of the BC subunit was solved in 1994 by Waldrop et al. [20] and was the first structure 
of a biotin dependent carboxylase (class I). Several three-dimensional structures of biotin 
dependent carboxylases have since been determined, and were found to share similar structural 
features between eukaryotes and prokaryotes [20, 21].  
The overall fold of BC places this enzyme in the ATPgrasp superfamily of enzymes. 
ATPgrasp enzymes typically fold into three domains referred to as either the A-, B-, and C-
domains or the N-terminal, central, and C-terminal domains [18]. The three-dimensional 
structure of BC from E. coli revealed this enzyme folds into three domains, an A-domain, a B-
domain, and a C-domain [20]. While the A- and C-domains are located next to each other 
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(Figure 1.7 A, Dark Purple and Light Purple), the B-domain is separate from the main structure 
of the enzyme (Figure 1.7 A, Yellow). This gives the BC subunit a clam-like shape, which 
allows for the B-domain to be mobile. When ATP binds during catalysis, the B-domain rotates 
45o, closing over the active site (Figure 1.7 B) thereby isolating the active site pocket [18].  
A. 
 
Figure 1.7. Structure of Monomeric Biotin Carboxylase Subunit of Acetyl-CoA Carboxylase in 
E. coli. The A-, B- and C-domain are dark purple, yellow, and light purple, respectively. A. 
Structure of the biotin carboxylase in the absence of substrates. The B-domain is in the open 
position B. Structure of biotin carboxylase in the presence of ATP. The B-domain (yellow) 
moves 45° to close over the active site when bound to the nucleotide. ATP is depicted in blue in 
the active site pocket. 
 
A.) 
 
B.) 
 
	
450 
B. 
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 1.2.3.1.2 Catalytic Mechanism of Biotin Carboxylase 
 The substrates of the first half-reaction, catalyzed by BC, follow a sequential ordered 
kinetic mechanism, meaning all substrates must bind to the enzyme for catalysis to occur [22]. 
While ATP and bicarbonate bind in a random order, the substrate biotin binds third. As is 
common in class I carboxylases, the mechanism of catalysis involves the formation of a 
carboxyphosphate intermediate [18]. This intermediate forms when an electron pair on an 
oxygen of bicarbonate attacks the gamma phosphorous atom of ATP.  
Though the mechanism for the formation of the carboxyphosphate has been determined, 
there are two postulated mechanisms for the transfer of the carboxyl group from 
carboxyphosphate to the N1′ of biotin [23]. In the first mechanism, the carboxyphosphate 
intermediate spontaneously decomposes forming phosphate and CO2, and the electron pair on the 
phosphate anion abstracts the proton from the N1′ of biotin, generating an enolate intermediate. 
The enolate intermediate then attacks the carbon atom of CO2, forming carboxybiotin. In the 
second mechanism, the carboxyphosphate intermediate participates in substrate assisted 
catalysis, where the electrons on the bridging oxygen atom of carboxyphosphate deprotonate the 
N1′ of biotin. The resulting enolate then attacks the carbon atom of the carboxyl group to form a 
dianionic tetrahedral intermediate. Originally, the first mechanism was generally agreed upon 
despite the lack of experimental evidence, due to the strong electrophilic properties of CO2. 
However, comparison of the three-dimensional structures of the BC subunit bound to either 
phosphate or the biotin analogue N1’-methoxycarbonyl biotin methyl ester indicate the second 
mechanism is more likely [24]. The crystal structure of phosphate bound to BC revealed the 
residues that stabilize the phosphate are positively charged [18]. When BC was crystallized in 
the presence of the biotin analog, the methyl ester group, which corresponds to the carboxyl 
  13 
group of carboxybiotin, was found to bind in the phosphate binding site and interact with the 
same positively charged residues [24]. As these residues have already been shown to bind the 
dianionic tetrahedral phosphate, it is likely these same residues stabilize the dianionic tetrahedral 
intermediate that occurs in the second mechanism. In further support of the second mechanism, 
other members of the ATPgrasp superfamily have been shown to proceed via direct attack on the 
carboxyphosphate intermediate [25].  
Structural studies of BC in the presence of the ATP analogue, AMPPCP, and in the 
absence of biotin indicate that the location of the substrates in the active site aids in catalysis of 
BC [24]. When ATP is present, and biotin absent, ATP is 5.8 Å from bicarbonate, ensuring that 
in the absence of biotin there is no appreciable hydrolysis of ATP. Thus, for catalysis to occur 
the distance between bicarbonate and ATP must be decreased. It is possible that “compression” 
of the substrates occurs upon biotin binding, which would facilitate the activation of bicarbonate 
to the carboxyphosphate intermediate. Structural studies also helped to explain a phenomenon 
exhibited by BC: substrate induced synergism. Though BC exhibits a bicarbonate dependent 
ATPase that can be measured in the absence of biotin, the binding of biotin increases ATP-
hydrolysis 1000-fold [26]. This increase in activity could be due to “compression” of the 
substrates bicarbonate and ATP, upon the binding of the third substrate biotin [24]. 
1.2.3.1.3 Quaternary Structure of Biotin Carboxylase in E. coli, and the Implications for 
Catalysis 
 
Biotin carboxylase in E. coli forms a homodimer (Figure 1.8) in which the monomers 
contain structurally independent active sites [20]. These active sites alternate during catalysis, 
and exhibit negative cooperativity, meaning one active site must complete a reaction in its 
entirety before the active site on the opposing monomer can be utilized [27]. This was observed 
when a kinetically inactive mutant monomer of BC was paired with a wild type (and therefore 
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catalytically active) monomer of BC and tested for activity. If the active sites acted 
independently there would have been a 50% decrease in activity observed as the active monomer 
would continue to catalyze the reaction unimpeded by the inactive monomer. Studies showed, 
however, that there was a 96% decrease in activity, indicating the active sites do not act 
independently, but activity of the enzyme is limited by the activity of the slowest monomer [27]. 
           
Figure 1.8. Three-Dimensional Structure of the BC Homodimer. The monomers of BC are 
yellow and green. 
  
1.2.3.2 Carboxyltransferase 
1.2.3.2.1 Three-Dimensional Structure of Carboxyltransferase 
Carboxyltransferase catalyzes the second half-reaction in ACC (Scheme 1.1). The crystal 
structure of the CT domain from yeast was determined in 2003 [28], and the bacterial three-
dimensional structure was determined in 2006 [29]. The yeast CT macromolecular structure is a 
homodimer with each monomer containing two domains: an N-terminal domain and a C-terminal 
domain [28]. These domains dimerize head-to-tail, with the N-terminal domain of one monomer 
binding the C-terminal domain of the second monomer (Figure 1.9 A). In contrast, the 
macromolecular structure of bacterial CT is composed of two different gene products which 
form an α2β2 heterotetramer (Figure 1.9 B, Pink and Blue, respectively) [28]. The crystal 
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structure of bacterial CT also showed the presence of a zinc finger domain, which is absent in the 
eukaryotic CT [29].  
A.                                                                            B. 
        
Figure 1.9. Crystal Structures of Yeast and Bacterial Carboxyltransferase. A. Yeast 
carboxyltransferase. One monomer is in blue, and the second monomer is in pink. The active 
sites are denoted by the arrows. B. Staphylococcus aureus carboxyltransferase. The α subunit is 
in pink while the β subunit is in blue. The active sites are denoted by the arrows. 
 
Despite these structural differences, the yeast CT and bacterial CT share distinct 
similarities. The tertiary structures of yeast CT and bacterial CT resemble each other, which is 
unsurprising as the C-terminal and N-terminal domains of yeast CT mimic the α and β subunits 
of bacterial CT, respectively. Furthermore, both the bacterial CT and yeast CT contain two active 
sites that are located between the subunits indicated by the arrows in Figure 1.9. Crystal 
structures indicate the N-terminal domain of yeast CT most likely binds acetyl-CoA, while the 
C-terminal domain of yeast CT binds carboxybiotin [28]. This binding mechanism is mimicked 
in bacteria, where the active sites for CT lie between the α and β subunits, with the α subunit 
most likely binding carboxybiotin and the β subunit binding acetyl-CoA [29]. 
The overall fold of the structure of CT places this enzyme in the crotonase superfamily of 
enzymes, which is characterized by the presence of a specific structural region, referred to as the 
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crotonase fold that contains an oxyanion hole, composed of two peptidic NH groups (Figure 
1.10, Blue) [29]. Both the α and β subunits of bacterial ACC contain this fold, which suggests 
that the proteins arose from gene duplication [30]. 
A.                                                                       B. 
                         
Figure 1.10. Crystal Structure of the Crotonase Fold from Bacterial Carboxyltransferase. A. The 
α subunit (green) with the crotonase fold in blue. B. The β subunit (green) with the crotonase 
fold in blue. 
 
1.2.3.2.2 Catalytic Mechanism of E. coli Carboxyltransferase. 
Though the exact catalytic mechanism of CT remains unknown, members of the 
crotonase superfamily of enzymes are known to stabilize enolates, indicating that both acetyl-
CoA and carboxybiotin form enolate anions as intermediates [29, 31]. Therefore, it is likely that 
acetyl-CoA is deprotonated by a base in the active site of the β subunit to form an enolate ion 
stabilized by the oxyanion hole in the crotonase fold. Simultaneously, the carboxybiotin 
decomposes to also form an enolate anion stabilized by the oxyanion hole in the α subunit. Once 
these anions are formed, the carbon of CO2 undergoes a nucleophilic attack from the enolate of 
acetyl-CoA, thereby forming malonyl-CoA [18, 31].  
The reaction catalyzed by carboxyltransferase in vivo is the transfer of the carboxyl group 
from carboxybiotin onto acetyl-CoA (Scheme 1.1). Due to the instability of carboxybiotin, 
however, the isolated carboxyltransferase reaction is assayed in the reverse direction in which 
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malonyl-CoA is decarboxylated to produce acetyl-CoA. The substrates for CT follow an ordered 
mechanism, with malonyl-CoA binding first followed by the biotin analogue, biocytin [32]. 
Biocytin is biotin with a lysine residue attached to the valeric acid side chain and is used because 
the Vmax is 3-fold higher than when using biotin as a substrate [33]. As biotin is covalently linked 
to BCCP via a lysine residue, the molecule biocytin mimics the biotin residue when attached to 
BCCP. This suggests that CT preferentially binds the physiological form of biotin, thereby 
lowering the likelihood of free biotin binding nonproductively to the CT subunit.  
1.2.3.3 Biotin Carboxyl Carrier Protein 
 The third protein in bacterial ACC is the BCCP subunit, which contains the vitamin 
biotin, covalently linked to residue K122 in E. coli [34]. Bacterial BCCP is composed of two 
domains connected by a proline alanine rich linker, which causes the 16.7 kDa protein to migrate 
high (22 kDa) on an SDS-PAGE gel [35]. These domains are the N-terminal domain, comprising 
the first 71 residues of the protein, and the C-terminal domain, comprising the last 80 residues. 
Though much is known about the C-terminal domain of BCCP, information pertaining to the N-
terminal domain is minimal.  
Currently, there is no structural data for full-length BCCP due in part to its tendency to 
aggregate [36]. However, the three-dimensional structure of the bacterial C-terminal domain has 
been determined via x-ray crystallography [37] and NMR [38, 39]. The structure of this domain 
consists of two symmetrical halves made up of four-stranded anti-parallel beta sheets creating a 
hydrophobic core (Figure 1.11) [37, 38, 39]. The determination of the three-dimensional 
structure of the C-terminal domain of BCCP revealed the presence of a region that extends out 
from the C-terminal domain consisting of residues Thr94-Ly100. This region was denoted the 
‘thumb’ (Figure 1.11), due to its shape. The thumb region is absent from other forms of ACC, 
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such as human ACC [40], as well as other biotin dependent enzymes, such as transcarboxylase 
[41]. The purpose of the thumb has yet to be confirmed; however, there is data to suggest that the 
thumb may be required for ACC catalysis, as deletion of the thumb led to a decrease in growth 
rate [42]. An in vivo study, which demonstrated deletion of the thumb led to a decrease in the 
product of ACC, malonyl-CoA, supports this theory [personal communication, Grover Waldrop]. 
Both the biotinylated and unbiotinylated structures of the C-terminal domain of bacterial 
BCCP have been determined [37, 38, 39]. Comparison of these structures gave insight into the 
effect of biotinylation on the protein. In the three-dimensional structure of the unbiotinylated C-
terminal domain of BCCP in E. coli, the thumb was shown to be highly flexible [37, 38]; 
however, the three-dimensional structure for the biotinylated C-terminal domain of BCCP in E. 
coli showed that biotinylation stabilized this region [39]. Furthermore, the biotin was shown to 
interact via a hydrogen bond with residue Thr94 (Figure 1.11) [39]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.11. Crystal Structure of Biotinylated Biotin Carboxyl Carrier Protein from E. coli. 
Biotin is blue, and the thumb is denoted on the structure. 
 
As mentioned above, very little is known about the N-terminal domain of bacterial 
BCCP. Though there is some evidence that this domain is involved in formation of the BC-
BCCP complex in E. coli [43] a crystal structure of BC bound to BCCP refutes this conclusion 
Thumb 
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[44]. Furthermore, there is no structural data available for the NTD, most likely due to its 
propensity to aggregate [36], which is similar to full-length BCCP [43, 45]. Interestingly, though 
most eukaryotic BCCP contain a domain homologous to the C-terminal domain in bacteria, there 
is no homologue to the N-terminal domain. 
1.3 Quaternary Structure of Acetyl-CoA Carboxylase 
1.3.1 Bacterial Quaternary Structure of Acetyl-CoA Carboxylase 
Currently, there is no three-dimensional structure of ACC in toto; however, the three-
dimensional structure of the BC-BCCP complex in E. coli was published by Broussard et al. 
[44]. To obtain the protein, BC and BCCP were overexpressed extragenomically and purified via 
His-tag on the N-terminus of BCCP. The purified protein complex was then crystallized, and the 
three-dimensional structure determined.  
In the complex, the ratio of BC to BCCP is 1:1, consisting of four BC subunits and four 
BCCP subunits (Figure 1.12 A). The BC homodimers (Pink and Blue) form a homotetramer that 
are fitted together at a 45° angle (Figure 1.12 B), and are held together by the C-terminal domain 
of BCCP (Yellow, Green and Blue), which act as molecular clips. In this structure, there was no 
electron density for the N-terminal domain of BCCP, despite the fact that full-length BCCP had 
been overexpressed. To confirm the N-terminal domain was present and had not been cleaved, 
the authors performed two assays. First, a crystal of the BC-BCCP complex was analyzed via 
SDS-PAGE. The band for BCCP was visible at the correct molecular weight for the full-length 
protein, indicating the N-terminal domain was present. Second, a Western blot was performed 
using a His-tag antibody, targeting the His-tag on the N-terminus of BCCP. If the N-terminal 
domain of BCCP had been cleaved, then the antibody would not have bound. Full-length BCCP 
was visible, thus, the N-terminal His-tag was present, and by inference full-length BCCP. 
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A.  
B.                       
                                   
Figure 1.12. Three-Dimensional Structure of Bacterial Biotin Carboxylase-Biotin Carboxyl 
Carrier Protein Complex. The two BC homodimers are in pink and blue. The four biotin 
carboxyl carrier proteins are green, yellow, blue, and red. A. Side view of the complex. B. 90° 
rotation view from the bottom of the complex. The BC homodimers are at a 45° angle to each 
other, while the C-terminal domains of BCCP hold the BC homodimers together acting as 
molecular clips. 
 
 
 
900 
  21 
1.3.2 Eukaryotic Quaternary Structure of Acetyl-CoA Carboxylase 
 
The crystal structure of eukaryotic ACC from yeast (Figure 1.13) shows that the enzyme 
is a homodimer [46]. The structure is in the shape of a quarter of a disk with a large channel 
through the center of the enzyme. This is proposed to be where the BCCP domain (Figure 1.13, 
Blue) of strand one (space filling model) translocates to transfer the carboxybiotin moiety from 
BC (Figure 1.13, Red) of strand one (space filling model) to CT (Figure 1.13, Pink). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.13. Crystal Structure of the Homodimer of Yeast Acetyl-CoA Carboxylase. Chain one 
is a space filling model (red BC (labelled), green BT, blue BCCP (labelled), yellow central 
regions, and pink CT (labelled)) while chain two is in ribbons (red BC, green BT, blue BCCP, 
yellow central regions, and pink CT.) The structure is in the shape of a quarter of a disk. The 
channel where BCCP translocates is represented by an oval in the center of the diagram. 
 
The three-dimensional structure revealed the presence of a previously unknown domain, 
referred to as BT (Figure 1.13, Green). The BT domain is located between the BC and CT 
domains of the same protomer to facilitate interactions between the catalytic domains. The BT 
BC 
CT 
BCCP 
CT 
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domain in yeast ACC is similar in both structure and function to the BT domain in propionyl-
CoA carboxylase, a biotin dependent enzyme involved in odd chain fatty acid oxidation [47].  
The three-dimensional structure of yeast ACC also reconciled two seemingly conflicting 
observations of eukaryotic BC. When the gene coding for the BC domain from yeast is 
overexpressed and purified, it is a catalytically inactive monomer [21]. Alternatively, when the 
gene coding for the holoenzyme of ACC (the entire polypeptide chain including BC, CT, and 
BCCP) is overexpressed and purified, the BC domains on opposing protomers form a 
homodimer similar to that of E. coli BC [20, 46]. The interaction of the BC domains from 
opposing protomers induces a conformational change in BC, causing it to become catalytically 
active. Why the BC domain, when overexpressed and purified separately, is found as a monomer 
is not known, however, it is hypothesized that the BC-BC interface has weak interactions, which 
are overcome when the rest of the polypeptide is present [46].  
1.4 Metabolic Regulation in Acetyl-CoA Carboxylase 
1.4.1 Regulation of Bacterial Acetyl-CoA Carboxylase 
1.4.1.1 Transcriptional Regulation of Biotin Carboxylase-Biotin Carboxyl Carrier Protein 
The BCCP subunit was found to regulate transcription of the genes coding for BC (accC) 
and BCCP (accB), which are located in an operon in E. coli (accBC) at 73.35 min [36]. James 
and Cronan report that overexpression of BCCP extragenomically represses production of the 
native transcript of the accBC operon. In contrast, if the plasmid contains both accB and accC, 
there is no reduction of native transcript, indicating that transcription levels are only down-
regulated in the event that BCCP is at a higher concentration than BC. Furthermore, 
overexpression of the gene coding for the isolated C-terminal domain of BCCP has no effect on 
the level of accBC transcript, whereas overexpression of the gene coding for the isolated N-
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terminal domain of BCCP represses production of the native transcript. Therefore, the N-
terminal domain of BCCP regulates the stoichiometric ratios of two major components of ACC 
[36]. Though the mechanism of repression is not known, it is unlikely BCCP interacts directly 
with the native promoter [personal communication, Grover Waldrop].  
1.4.1.2 Translational Regulation of Carboxyltransferase 
 Carboxyltransferase down-regulates its own translation by binding the mRNA for the α 
and β subunits via the zinc finger domain [48]. It is important to note that the α and β subunits of 
CT are located on opposite ends of the genome in E. coli (at 4.5 min and 52.4 min, respectively), 
and thus have distinct mRNAs [49]. During log phase, when acetyl-CoA concentrations are high, 
CT preferentially binds acetyl-CoA over its mRNA. Alternatively, when acetyl-CoA 
concentrations are low (for example during stationary phase), the CT subunit binds the mRNA of 
the α and β subunit competitively versus the substrate acetyl-CoA [48]. Carboxyltransferase 
binding its mRNA has a three-fold effect. First, by binding the mRNA, CT is down-regulating its 
own translation, therefore preventing wasteful energy expenditure in the absence of acetyl-CoA. 
Second, CT binding the mRNA of the α and β subunit ensures both subunits are produced at a 
stoichiometric ratio, despite being located at two distinct loci in the genome. Third, mRNA 
inhibits catalysis of the CT subunit, thus down-regulating fatty acid synthesis during stationary 
phase. Thus, CT acts as a “dimmer switch” allowing the cell to respond to changes in acetyl-CoA 
concentrations [48].  
1.4.1.3 Regulation of the Macromolecular Complex 
Acetyl-CoA carboxylase is also regulated via feedback inhibition by acyl-ACPs which 
are the downstream intermediates of fatty acid synthesis (FAS) [50]. At high concentrations of 
acyl-ACPs, ACC was down-regulated to a maximum amount of 70%, indicating that high 
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concentrations of acyl-ACPs cannot completely abolish ACC activity. This mechanism causes 
fatty acid synthesis to significantly decrease, while still maintaining a minimal amount of fatty 
acid production. 
The macromolecular structure of bacterial ACC was found to exhibit substrate induced 
synergism [17] meaning acetyl-CoA must be present for ATP hydrolysis to occur. This 
regulation prevents wasteful hydrolysis of ATP when acetyl-CoA concentrations are low, such as 
in stationary phase or starvation. 
1.4.2 Regulation of Acetyl-CoA Carboxylase in Humans  
1.4.2.1 Background 
 In humans, there are two isoforms of ACC: ACC1 and ACC2. As in most eukaryotes, the 
proteins for human ACC (BC, BCCP, and CT) are organized into domains on a single 
polypeptide chain [18]. ACC1 is a 265 kDa protein located in the cytosol and is expressed in 
greater amounts in lipogenic tissue, such as the mammary glands, and adipose tissue [51]. ACC2 
is a 280 kDa protein located in the mitochondria, and is expressed at higher concentrations in 
oxidative tissues, such as the heart and skeletal muscle [52]. Both ACC1 and ACC2 are also 
expressed in high concentrations in the liver.  
Just like in bacteria, ACC in humans catalyzes the ATP-dependent carboxylation of 
acetyl-CoA to form malonyl CoA; however, the role of the two isoforms differs greatly. 
Malonyl-CoA produced by ACC1 proceeds into fatty acid synthesis in the cytoplasm. 
Alternatively, malonyl-CoA produced by ACC2 acts as an inhibitor to the enzyme carnitine 
palmitoyl transferase, which is the enzyme responsible for transporting fatty acids into the 
mitochondria to be broken down by fatty acid oxidation. Both isoforms of human ACC are 
highly regulated. 
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1.4.2.2 Regulation of Polymerization of Human Acetyl-CoA Carboxylase 
Activity of both ACC1 and ACC2 are increased by polymerization of the enzymes [53]. 
In the fed state, citrate levels in the cell increase dramatically, upregulating polymerization of the 
enzyme which increases activity of ACC up to 50% [54]. This polymerization has a twofold 
effect. First, via ACC1, this increases the production of fatty acids, which can then be stored for 
energy. Second, via ACC2, this decreases degradation of fatty acids from fatty acid oxidation, 
preventing the utilization of stored energy. Alternatively, polymerization of ACC1 is inhibited by 
high concentrations of palmitoyl-CoA, the end product of FAS [55]. Thus, if there is an 
abundance of product from FAS, the flux through the pathway is down-regulated, causing a 
decrease in fatty acid production via ACC1. As accumulation of palmitoyl-CoA is only in the 
cytosol, high levels of palmitoyl-CoA do not affect ACC2, meaning that ACC2 will not be 
down-regulated, and transfer of fatty acids into the mitochondria does not increase.  
1.4.2.3 Regulation by Phosphorylation of Human Acetyl-CoA Carboxylase 
Activity of ACC1 and ACC2 is also inhibited by phosphorylation when nutrients are 
scarce [56]. When glucose levels are low, and/or during starvation AMP levels increase leading 
to the activation of AMP-activated kinase (AMPK), which phosphorylates ACC1 and ACC2, 
thereby inhibiting activity [57]. This down-regulation of ACC1 allows the cell to halt fatty acid 
synthesis, while down-regulating ACC2 alleviates the inhibition on carnitine acyl transferase, 
thus increasing transport of excess fatty acids into the mitochondria to be oxidized and used for 
energy. 
There are eight reported phosphorylation sites on ACC1 and ACC2 [47]. Though the 
mechanism of inhibition for most of the sites is unknown, the purpose of the phosphorylation site 
Ser80 on ACC1 and Ser222 on ACC2 has been reported [47]. Ser80 on ACC1 and Ser222 on 
  26 
ACC2 are located on the BC-BC interface of their respective isoforms. As noted above, the BC 
domain in eukaryotes is only catalytically active when interacting with another BC domain to 
form a dimer [21]. When the serine residues located on the interface are phosphorylated, activity 
is inhibited because the BC domain on one protomer of the holoenzyme is prevented from 
interacting with the other BC domain on the second protomer of the holoenzyme. Alternatively, 
dephosphorylation allows the BC domains on opposing protomers to interact thereby becoming 
catalytically active [47]. Ser80 on ACC1 or Ser222 on ACC2 is most likely a target due to the 
fact that the interactions holding the BC-BC domains together are weak. Therefore, it is possible 
that in the holoenzyme the BC domains of strand one and two associate and disassociate 
continuously, allowing access to Ser80 on ACC1 and Ser222 on ACC2.  
This type of regulation is also exhibited on Ser 1157 in yeast [58]. Interestingly, the 
natural product soraphen A has been shown to inhibit yeast BC by binding in the BC-BC 
interface of acetyl-CoA carboxylase. In fact, the soraphen A binding site includes Ser1157, 
indicating that this mechanism of inhibition prevents the BC-BC interactions, which is consistent 
with the regulatory mechanism of phosphorylation/dephosphorylation.  
1.4.2.4 Transcriptional Regulation of Human Acetyl-CoA Carboxylase 
The regulation of ACC1 at the transcriptional level is based on control of three promoters 
(PI, PII, and PIII) [59]. All three promoters are activated by insulin and the synthetic 
glucocorticoid dexamethasone [60]. Though the mechanism is not well understood, both insulin 
and glucocorticoids are well documented to have an anabolic effect on lipid metabolism [60], 
thus the finding that these hormones activate ACC1 is unsurprising. The PI and PII promoter are 
active in all human tissue, whereas the PIII promoter is active in the heart, brain, skeletal muscle, 
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and adipose tissue [59]. PI is constitutively expressed, while PII and PIII are subject to control 
based on diet and hormones [59].  
One example of transcriptional regulation in ACC1 is the binding of sterol regulatory 
element binding protein-1a (SREBP-1a) to the PII promoter [59]. SREBP-1a is a member of the 
SREBP family of enzymes, and is attached to the endoplasmic reticulum. At low levels of 
sterols, such as cholesterol, this protein is cleaved from the ER and binds to the sterol regulatory 
element DNA sequence, located in the PII promoter. Conversely, high concentrations of sterols, 
such as cholesterol, prevent cleavage from the nuclear membrane, thus preventing activation of 
ACC1 transcription. The physiological implication for this regulation is not well understood in 
human ACC1. It is interesting to note, however, transcription of the gene coding for the first 
committed step in cholesterol biosynthesis, HMG-CoA reductase, is similarly activated by 
SREBP-1a [61]. As cholesterol biosynthesis also begins with acetyl-CoA, it is possible there is 
some evolutionary connection between the two.  
ACC2 has also been shown to have three promoters (P0, PI, and PII); however, only PI 
and PII are functional in vivo [52]. PI is highly active in skeletal muscle and the heart, while PII 
is the primary promoter in the liver [62]. As with ACC1, PII in ACC2 is activated by insulin, 
glucocorticoids, and SREBP-1a [62].  
The promoters in both ACC1 (PI, PII, and PIII) and ACC2 (PI, PII) are subject to 
activation by a second sterol regulatory element binding protein, SREBP-1c [63]. SREBP-1c is a 
member of the same family as SREBP-1a, and is also activated by cleavage from the 
endoplasmic reticulum. SREBP-1c has been shown to similarly activate transcription of the 
enzymes required for triglyceride biosynthesis. This means the flux through FAS and the 
triglyceride biosynthesis pathway increase concomitantly. 
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1.4.2.5 The Role of DNA Secondary Structures in Regulation of ACC1 
DNA replication and transcription of ACC1 is negatively regulated by the formation of 
secondary structures in the promoters PI and PII, due to their rich G/C content. The high 
concentration of G and C allows the formation of a cube-like structure (Figure 1.14) from four 
guanines or four cytosines. These are referred to as the G-quadruplex, which forms in the 
template strand (Figure 1.14 A), and I-motif, which forms in the non-template strand (Figure 
1.14 B) [64, 65]. Formation of the G-quadruplex in ACC1 occurs spontaneously under 
physiological conditions, and has been shown to prevent DNA replication aided by TMPyP4, a 
small molecule which is known to stabilize G-quadruplexes [66]. Furthermore, formation of the 
G-quadruplex represses transcription by preventing transcription factors from binding such as 
Sp1, a protein that activates transcription of ACC1 [59]. Similar to the G-quadruplex, the I-motif 
also forms spontaneously; however, stability of this motif has been shown to increase when 
subjected to acidic conditions, high salt concentrations, negative DNA supercoiling, and 
molecular crowding (i.e. when the number of small molecules is high compared to the space and 
water supply available) [65]. Like the G-quadruplex, the I-motif secondary structure was also 
shown to inhibit DNA replication, as well as transcription of ACC1. This mechanism of 
regulation is most likely utilized to aid in the transition between log phase, when the cell 
replicates rapidly and ACC1 is overexpressed in abundance, to the stationary phase, when DNA 
synthesis and ACC1 transcription are down-regulated. 
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A.                                                                         B. 
                           
Figure 1.14. Drawings Representing the G-Quadruplex and I-Motif of PII in Human ACC1. A. 
G-quadruplex from the PII promoter of human ACC. The white represents unbound bases, and 
the red represent the guanosines forming the complex. Arrows in the structure indicate 
orientation of the strands. From Kaulage et al. [64] B. I-motif from the PII promoter of human 
ACC. The yellow are cytosines forming the structure, and the red are unbound bases. The arrows 
in the structure represent the direction of the strands. From Kaulage et al. [65].  
 
1.5 Acetyl-CoA Carboxylase as a Novel Target for Antibiotics 
1.5.1 Background 
 The major conclusion that can be taken from the various ways in which ACC is regulated 
in both human and bacteria is that the cell is able to regulate its metabolism to ensure the cell 
remains in homeostasis. The mechanisms of regulation mentioned above have thus far only been 
in response to changes in the availability of nutrients in the cellular environment. The growth 
rate of the cell can also be forcibly decreased by foreign toxins such as antibacterial agents. 
However, over time, a cell line will eventually augment its own genome to overcome these 
foreign toxins, creating a resistant strain. 
The WHO categorizes antibacterial resistance as one of the biggest threats to the modern 
world [66]. Though resistance occurs naturally, the process has been accelerated by the over 
prescription of antibiotics and the excessive use in agricultural practices. Thus, new antibacterial 
agents are in constant demand. Unfortunately, development of antibiotics over the last 30 years 
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has concomitantly decreased [67], and as a result, a ‘post antibiotic era’ is rapidly approaching, 
where common infections will once again be deadly [68]. Knowing this, scientists have begun 
research into novel antibacterial targets.  
The development of an effective antibacterial agent with low side effects must fulfill 
three requirements: first, the antibacterial agent must be specific to the bacterial target, and 
therefore not affect, or only minimally affect, the eukaryotic homologue; second, the 
antibacterial agent must have the ability to affect both Gram-negative and Gram-positive bacteria 
(i.e. be broad spectrum); and third, the effect of the antibacterial agent must be either bactericidal 
or bacteriostatic [69]. The fatty acid synthesis (FAS) pathway in bacteria meets all three 
conditions. The enzymes involved in FAS in eukaryotes are located on a single polypeptide 
chain, whereas in bacteria these enzymes are distinct gene products [16, 18], thus any 
antibacterial agent that targets the bacterial proteins would most likely not affect the eukaryotic 
proteins. Furthermore, the enzymes in FAS from many human pathogens share homology and 
biochemical properties, indicating that an antibacterial agent has the opportunity to be broad 
spectrum [70]. Finally, the product of FAS, palmitoyl-CoA, is used in membrane biogenesis, 
thus the inhibition of this pathway would be bactericidal.  
As ACC plays a critical role in FAS, inhibitors of this enzyme could be used as novel 
antibacterial agents. ACC was first validated as a target when Pfizer determined that a mutation 
in the CT subunit of ACC caused a mutant strain of Staphylococcus aureus to be temperature 
sensitive, indicating that ACC is critical for cell growth [personal communication, Grover 
Waldrop]. GlaxoSmithKline confirmed this when they were unable to make a mutant strain of 
bacteria lacking the ACC gene [personal communication, Grover Waldrop]. There are currently 
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no commercially available antibacterial agents targeting ACC, making it an ideal target for novel 
antibacterial agent development. 
1.5.2 Biotin Carboxylase Inhibitors 
 The discovery of the first antibacterial agents targeting the biotin carboxylase subunit of 
ACC was unintended [71]. Scientists at Pfizer were screening whole cells against a library of 1.6 
million potential anti-cancer compounds that targeted tyrosine protein kinases when a class of 
compounds, referred to as the pyridopyrimidines, were found to exhibit antibacterial activity 
against Gram-negative bacteria and the Gram-positive bacterium Staphylococcus aureus. The 
potency of the pyridopyrimidines was significantly less for S. aureus, indicating specificity for 
Gram-negative pathogens. One of these compounds (compound 1) was determined to have a low 
Kd of 0.8 nM, and was used for further studies (Figure 1.15). In order to determine the target of 
this antibacterial activity, spontaneous mutations were generated in the Gram-negative pathogen 
Haemophilus influenza. Interestingly, the mutant strains that were shown to be resistant to the 
pyridopyrimidines all had mutations in the gene coding for the BC subunit of ACC. When the 
mutations were compared with the crystal structure for E. coli BC bound to ADP, it was found 
that the mutations were clustered in the ATP active site; this was unsurprising, given the original 
screening library targeted kinases, which also hydrolyze ATP. The three-dimensional structure of 
biotin carboxylase bound to compound 1 confirmed that compound 1 bound in the ATP site of 
BC. Furthermore compound 1 was shown to interact with isoleucine 437 in E. coli BC, whereas 
the resistant mutant strains contained a threonine at this residue, which causes a decrease in 
hydrophobic interactions between the inhibitor and the BC enzyme. The equivalent residue to 
437 in Gram-positive bacteria is also a threonine, indicating why compound 1 is more potent 
versus Gram-negative bacteria.  
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Compound 1 
Figure 1.15. Structure of Pyridopyrimidine Inhibitor of Biotin Carboxylase. 
 The discovery of the pyridopyrimidines led to further investigation into biotin 
carboxylase inhibitors [72]. Using a virtual screen of 2.2 million compounds, 525 compounds 
were found to share pharmacophore features with compound 1 [72]. Of these compounds, 48 
inhibited BC with an IC50 value of less than 10 µM. In the same study, a biochemical screening 
of 5200 fragments (molecules with a MW of 250 kDa or less) were analyzed, giving a total of 
142 fragments that inhibited BC with IC50s in the micromolar range. Comparison of the 
compounds from both screens found that all compounds shared hydrogen bond donors and 
acceptors similar to those in compound 1. These similarities are circled on compound 1 and one 
of the compounds from these screens, an amino-oxazole derivative, denoted as compound 2, in 
Figure 1.16. A crystal structure of compound 2 bound to BC, revealed that the compound bound 
in the ATP binding site of BC in the same manner as the pyridopyrimidines. Studies also showed 
that compound 2 did not inhibit eukaryotic ACC, or 40 protein kinases tested, indicating that it is 
highly specific to the bacterial BC subunit. 
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Compound 1      Compound 2  
  
Figure 1.16. Inhibitors of Biotin Carboxylase. 1 Pyridopyrimidine 2 Amino-oxazole derivative. 
Pharmacophore similarities between the compounds are circled. 
 
Though fragment based screening has the advantage of testing large libraries of 
compounds, most compounds bound with low affinity [73]. In order to increase the potency of a 
potential antibacterial agent, fragment-to-lead optimization was employed. While compound 1 
was shown to bind more tightly to BC than the amino-oxazole derivative, compound 2 is more 
synthetically tractable and therefore was used to discover more potent inhibitors of BC. By 
extending the amino-oxazole derivative as in compounds 3 and 4 (Figure 1.17), Pfizer was able 
to maximize interactions with the ATP binding site, giving rise to inhibitors with 200- and 3000-
fold higher IC50 values, respectively [72].  
In a separate study by Cheng et al. a third class of compounds was found to inhibit the 
BC subunit in bacterial ACC [74]. This class of compounds is referred to as the benzimidazole 
carboxamides. Crystallographic studies of the benzimidazole carboxamides bound to BC showed 
that these inhibitors also bind in the ATP site. However, unlike both the pyridopyrimidines and 
amino-oxazole, the benzimidazole carboxamides were found to have the added benefit of being a 
broad spectrum antibacterial. Furthermore, this class of antibacterial agents did not affect 
eukaryotic ACC, protein biosynthesis, or human kinases, indicating this class of inhibitors has 
high specificity for bacterial BC.  
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Compound 3     Compound 4 
 
Figure 1.17. Hit-to-Lead Results of Inhibitors of Biotin Carboxylase. 3 Amino-oxazole 4 
Amino-oxazole derivative. 
 
1.5.3 Carboxyltransferase Inhibitors. 
1.5.3.1 Inhibiting Carboxyltransferase via the Active Site 
 Unlike BC, there is only one class of compounds that has been shown to inhibit the 
carboxyltransferase subunit of CT and have antibacterial activity. This class of compounds is 
referred to as the pyrrolidinediones, which are characterized by the pyrrolidinedione head group 
(Figure 1.18, Compound 5) [75]. The first of this class of inhibitors discovered was the natural 
product andrimid, (Figure 1.19, compound 6) which was found in the broth culture of an 
Enterobacter sp., an intracellular symbiont of the brown planthopper insect. Andrimid was 
determined to be bactericidal versus Xanthomonas campestris pv. oryzae, a pathogen that is 
lethal to rice plants, on which the brown planthopper feeds [76].  
                                                                    
Compound 5 
Figure 1.18. 5 Pyrrolidinedione Head Group. 
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In a subsequent study, Needham et al. found that an isolate of Pseudomonas fluorescens 
was potent against methicillin resistant Staphylococcus aureus (MRSA) [77]. Examination of the 
isolate revealed that it contained the compound andrimid, as well as the compounds moiramide 
A, B, and C (Figure 1.19, Compounds 7, 8, and 9 respectively). Of the three moiramide 
derivatives, only moiramide B (compound 8) was shown to have antibacterial activity; this was 
unsurprising as moiramide B and andrimid possess the same pyrrolidinedione head group, only 
varying in the length of the fatty acyl tail. Alternatively, moiramide C (compound 9), which 
differs by a single functional group attached to the pyrrolidinedione head, did not exhibit 
antibacterial activity, indicating that while the fatty acyl tail may be subjected to significant 
alterations, the chemical components of the head group are more rigidly controlled. This is in 
agreement with a study by Pohlmann et al. in which the authors conducted a structure activity 
relationship on the head group and found that the pyrrolidinedione head could not withstand 
alterations and retain antibacterial properties [78].  
        
Compound 6     Compound 7 
         
Compound 8     Compound 9 
 
Figure 1.19. Pyrrolidinedione Compounds Found in the Broth Culture of an Enterobacter sp. 6 
Andrimid. 7, 8, and 9 Moiramide A, B, and C, respectively.  
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Kinetic studies revealed that both andrimid and moiramide B were inhibitors of the CT 
subunit of ACC, with moiramide B being the more potent inhibitor [76, 77]. Moiramide B was 
shown to have IC50s in the nanomolar range against the CT subunit of ACC in both Gram-
negative and Gram-positive organisms. In contrast, moiramide B did not affect eukaryotic ACC, 
indicating it could be used as a new broad spectrum antibacterial agent; however, there are no 
studies published on the activity of this compound in vivo.  
A crystal structure of moiramide B (compound 8) bound to the CT subunit from 
Staphylococcus aureus revealed that compound 8 binds in the active site, which is at the 
interface of the α and β subunits. This is consistent with the fact that moiramide B exhibits 
competitive inhibition versus malonyl-CoA [77]. The head group (Figure 1.20, Compound 8) of 
moiramide B forms hydrogen bonds with glycine 208, alanine 168, glycine 166, and glycine 232 
of the β subunit, and serine 198 of the α subunit [79]. These residues are conserved between 
Gram-negative and Gram-positive organisms, which explains why moiramide B is a broad 
spectrum antibacterial agent [28, 30]. Furthermore, glycine 208 is part the oxyanion hole of the β 
subunit involved in stabilizing the acetyl-CoA enolate anion. When moiramide B binds the 
carboxyltransferase subunit, the amide hydrogen of Gly208 interacts with both the C2 and C5 
carbonyl groups on the pyrrolidinedione head, which are circled in Figure 1.20. Conversely, the 
fatty acyl tail was shown to have weak interactions with CT. Structure activity relationships of 
moiramide B in which the fatty acyl tail was deleted (compound 10), showed little difference in 
inhibition between the two compounds. However, compound 10 was shown to have no 
antibacterial activity, indicating that the fatty acyl tail is most likely only involved in the 
transport of the molecule into the bacterial cell. This confirms the results by Pohlmann et al. that 
the fatty acyl tail is not required for inhibition [78, 79].  
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    Head Group 
Compound 8    Compound 10 
 
Figure 1.20. Moiramide B and Compound 10. Head group of moiramide B is labelled. 
 
1.5.3.2 Inhibiting Carboxyltransferase via the Zinc Finger Domain 
The carboxyltransferase subunit of bacterial ACC also contains a zinc finger domain 
separate from the active site [28]. This domain has been shown, as previously noted, to bind the 
mRNA of CT competitively versus the substrate acetyl-CoA [48], indicating the active site and 
the zinc finger domain communicate. As the zinc finger domain is present in both Gram-negative 
E. coli and Gram-positive Staphylococcus aureus CT [28] but absent from eukaryotic ACC [27], 
an inhibitor which binds the zinc finger domain could lead to the discovery of novel antibacterial 
agents that are both broad spectrum and specific to bacterial ACC.  
1.5.4 Acetyl-CoA Carboxylase Complex Inhibitors 
 As mentioned above, ACC has been shown to form a complex that is required for 
catalysis [17]. This discovery leads to the possibility for the development of antibacterial agents 
that inhibit the protein-protein interactions between the subunits. These types of inhibitors would 
be specific to bacterial ACC because eukaryotic ACC is on a single polypeptide chain, and 
therefore most likely does not contain these same protein-protein interactions (PPI). Though 
there is not a three-dimensional structure of bacterial ACC in toto, the BC-BCCP complex 
(Figure 1.12) may be used as a template to begin development of novel antibacterial agents, 
which target these interactions [44].  
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1.5.5 Development of Dual Ligand Inhibitors versus Acetyl-CoA Carboxylase to Mitigate 
Antibacterial Resistance. 
 
The major issue with all antibacterial agents is the inevitability of genetic mutations 
which lead to antibacterial resistance. Though this occurrence cannot be abrogated completely, 
dual-ligand inhibitors have been shown to lower the frequency of resistance [80, 81, 82]. Dual-
ligand inhibitors are chemical compounds that consist of two inhibitory moieties, linked by an 
aliphatic chain, where each moiety inhibits distinct proteins. Thus, the frequency of resistance 
decreases as missense mutations would have to occur in more than one gene to abolish 
inhibition. Being that ACC contains two enzymatic subunits (BC and CT), which are coded for 
on three genes not genetically linked [16], a minimum of three missense mutations would have to 
occur for the organism to become resistant.  
To determine the potentiality of a dual-ligand inhibitor as an antibacterial agent, amino-
oxazole and moiramide B were connected via a hydrophobic carbon chain of varying lengths 
[83]. In vitro kinetic assays revealed Compounds 11 and 12 (Figure 1.21) were able to inhibit 
ACC with Ki’s in the nM range. Only compound 12, which contains a 7-carbon linker, was 
shown to have antibacterial activity against most Gram-positive organisms and the efflux 
compromised E. coli strain lacking the tolC outer-membrane channel, indicating that 
modifications of this inhibitor could lead to a broad spectrum antibacterial agent. Furthermore, 
compound 12 was found to have a low spontaneous resistant frequency, meaning the bacteria 
affected are likely to become resistant to the dual ligand inhibitor at a slower rate. The inability 
of compound 11 to exhibit antibacterial activity was due to the extremely hydrophobic 15-carbon 
linker. This was overcome by co-incubating the cells with compound 11 and polymixin B 
nonapeptide, a small molecule that increases the ability of hydrophobic molecules to pass 
through the membrane, thereby enabling compound 11 to inhibit bacterial growth. Though 
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neither compound was able to inhibit growth of all wild-type bacteria, this study set a precedent 
for the further development of dual-ligand inhibitors of ACC.  
 
 
 
 
 
 
 
Figure 1.21. Dual Ligand Inhibitors of Acetyl-CoA Carboxylase Containing Amino-oxazole, 
Moiramide B, and a Hydrocarbon linker. 11 Hydrocarbon linker of 15 carbons. 12 Hydrocarbon 
linker of 7 carbons.  
 
1.6 Objectives and Rationale for Study 
Fatty acid synthesis accounts for 94% of all ATP usage in membrane biogenesis [84], 
thus ACC, which catalyzes the first committed step, must be tightly regulated. The purpose of 
this dissertation is to examine two distinct types of regulation of ACC, both of which give insight 
into the catalytic mechanism. In chapter 2, the mechanism of feedback inhibition by acyl-ACPs 
was determined. In this study, it was discovered that ACC exhibits a time dependent, or 
hysteretic, inhibition by the end product of FAS, palmitoyl-ACP. The hysteretic nature of ACC 
acts as a “surge protector” to mitigate the effect of short-term fluctuating metabolites in the FAS 
pathway. Furthermore, it was revealed that the inhibitory moiety of palmitoyl-ACP is the 
cofactor pantothenic acid, which is covalently attached to ACP. The implications of this study 
have far-reaching effects as pantothenic acid can be used as a scaffold to create novel 
antibacterial agents for ACC. Chapter 3 describes a mechanism of regulation in which the N-
11 (n)= 15 
12 (n)= 7 
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terminal domain of BCCP stabilizes the carboxybiotin intermediate. Computational modeling 
indicated that the N-terminal domain most likely lacks a stable three-dimensional structure, and 
thus is an intrinsically disordered protein, which helped to explain two enigmas. First, it explains 
why both the N-terminal domain and BCCP aggregate at high concentrations, and why any 
attempt to glean information on the structure of the N-terminal domain has been for naught. 
Second, it explains how the N-terminal domain can be involved in complex formation, 
transcriptional regulation, and stabilization of the carboxybiotin intermediate, as the ability of the 
N-terminal domain to fulfill multiple roles is characteristic of intrinsically disordered proteins. 
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CHAPTER 2. ACETYL-COA CARBOXYLASE IN ESCHERICHIA COLI 
EXHIBITS A PRONOUNCED HYSTERESIS WHEN INHIBITED BY 
PALMITOYL-ACYL CARRIER PROTEIN1 
 
2.1 Introduction  
Fatty acid synthesis (FAS) is the most energy intensive metabolic pathway in bacteria [1]. 
The first committed and highly regulated step of FAS is catalyzed by acetyl-CoA carboxylase 
(ACC). In most Gram-positive and Gram-negative bacteria, ACC is composed of three 
components, biotin carboxylase (BC), the 2-subunit carboxyltransferase (CT) and biotin carboxyl 
carrier protein (BCCP) [2]. These three components catalyze the carboxylation of acetyl-CoA to 
form malonyl-CoA via two half-reactions (Scheme 2.1) [2]. 
  
Scheme 2.1. 
 
In the first half-reaction, biotin carboxylase (BC) catalyzes the carboxylation of the 
vitamin biotin which is covalently attached to BCCP. Carboxyltransferase (CT) then catalyzes 
the transfer of the carboxyl group from biotin to acetyl-CoA, in the second half-reaction. Both 
the BC and the CT enzymatic functions can be isolated and exhibit activity separately [2]. 
However, isolated BC can only catalyze the reaction using free biotin (i.e. there is no ATP 
hydrolysis with biotinylated-BCCP as the substrate [3]). Moreover, the isolated CT function only 
                                                
This article was published in Archives of Biochemistry and Biophysics, 636, Evans A., Ribble 
W., Schexnaydre E., Waldrop GL. Acetyl-CoA Carboxylase in Escherichia coli exhibits a 
pronounced hysteresis when Inhibited by Palmitoyl-acyl Carrier Protein, 100-109, Copyright 
Elsevier (2017). 
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catalyzes the reverse reaction when malonyl-CoA reacts with free biotin analog, biocytin [4]. In 
contrast to the isolated components, the overall physiological reaction (Scheme 2.1) requires 
formation of a complex of the three components and the presence of acetyl-CoA [3]. 
Acetyl-CoA carboxylase is subject to several levels of regulation in order to mediate the 
flux of metabolites through FAS. One type of regulation is negative feedback inhibition on ACC 
by acylated-ACPs [5]. The initial observation suggesting acylated-ACP exhibited negative 
feedback inhibition came from overexpression of the gene coding for the protein thioesterase I 
(TesA'), which hydrolyzes the bond between fatty acids and ACP. When the level of this enzyme 
was increased, there was a concomitant increase in the flux of metabolites through fatty acid 
synthesis [6]. It was subsequently determined that ACP esterified to fatty acids with 6–20 carbon 
atoms inhibited the activity of both E. coli ACC [5], and plastidic ACC from Brassica napus [7]. 
Moreover, when some Gram-positive pathogens, such as Streptococcus agalactie, take up and 
utilize host fatty acids, endogenous fatty acid synthesis is completely inhibited, which indicates 
negative feedback inhibition of ACC [8]. Even though there is considerable evidence that 
indicates acylated-ACP is responsible for feedback inhibition of ACC, the exact mechanism of 
inhibition has not yet been determined, and therefore is the purpose of this study. In the original 
study of negative feedback inhibition of ACC by acylated-ACP, Davis and Cronan [5] found that 
ACP esterified with palmitic acid was the most effective acyl-ACP inhibitor of ACC. Therefore, 
all of the studies described hereafter utilize palmitoyl-ACP (PACP). A significant, yet 
unexpected, result of this study is that ACC formation exhibits a pronounced hysteresis. This 
hysteretic phenomenon mitigates excessive fluctuations in metabolites, thereby giving the cell 
more control over FAS. 
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A detailed understanding of the inhibition of ACC by acylated-ACP benefits both the 
biotechnology and pharmaceutical industries. The three-carbon product of ACC, malonyl-CoA, 
is the precursor to the industrial chemical 3-hydroxypropionic acid, which is used to synthesize 
polyacrylates [9,10]. Malonyl-CoA is also the building block for polyketides and flavonoids, 
which can be used as pharmaceutical agents [11]. Unfortunately, the intracellular concentration 
of malonyl-CoA is low (35 µM) [12,13], thereby limiting the production flux of the above 
chemicals. Theoretically, increasing the intracellular level of malonyl-CoA by up-regulating the 
activity of ACC should yield a significantly higher amount of product. Increased ACC activity, 
however, leads to higher flux through FAS, causing an increase in the downstream product, 
acylated-ACP, which in turn down regulates ACC. Therefore, to optimize malonyl-CoA 
production this feedback inhibition must be circumvented. The first step to this end is a thorough 
and detailed kinetic characterization of the mechanism of inhibition of E. coli ACC by acylated-
ACP. 
2.2 Materials and Methods 
2.2.1 Reagents  
Amicon Ultracentrifugal Filters (molecular mass cut off of 3,000, 10,000, and 50,000 
kDa) and Benzonase were from Millipore. M280 Streptavidin Dynabeads, and BL21 (DE3) E. 
coli chemically competent cells were obtained from Invitrogen. The Bradford Protein assay 
reagent, Opti-4CN substrate kit, and goat anti-mouse IgG (H+L)-HRP conjugates were 
purchased from Novagen. Kanamycin, streptomycin, IPTG, D-Lactose and PINKstain Protein 
Ladder were obtained from Gold Biotechnology. BioTrace PVDF Membranes were from PALL 
Life Sciences. The monoclonal mouse anti-His Tag antibodies were purchased from Genscript. 
Casamino acids were from Lab Scientific. The HiLoad 16/60 Superdex 200 prep-grade gel 
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filtration column, HisTrap HP Ni Sepharose and HiTrap DEAE FF column were purchased from 
GE Healthcare. Ni-NTA agarose was acquired from Qiagen. Protease inhibitor cocktail pellets 
were from Roche. ACP synthase, NdeI, BamHI, DNA polymerase and Gibson Assembly master 
mix were obtained from New England Biolabs. PfuII Ultra II hotstart PCR Master Mix was from 
Stratagene. DNA Clean and Concentrator kit was obtained from Zymo research.  The bacterial 
strain E. coli 10G was from Lucigen. All other reagents were purchased from Sigma Aldrich. 
2.2.2 Cloning, Expression, Purification, and Acylation of Acyl Carrier Protein.  
The gene coding for acyl carrier protein (ACP) was cloned from E. coli BX_591, a 
derivative of the plasmid BW25113 constructed at OPXBIO, and amplified using primers HL 
234, and HL 235 (Table 2.1).  The plasmid pET-28b was amplified separately with primers HL 
233, and HL 222 (Table 2.1).  PfuII Ultra II Hotstart PCR Master Mix was used in both PCR 
reactions according to the manufacturer’s instructions.  The PCR products were purified using 
the DNA Clean & Concentrator kit.  Plasmid pET-28-EcACP was constructed from the 
amplification products using the Gibson Assembly Master Mix according to the manufacturer’s 
instructions and the reaction mixture was transformed into E. coli 10G. The final plasmid 
construct was confirmed by DNA sequencing, and transformed into BL21 (DE3) E. coli cells for 
overexpression of the acyl carrier protein gene.  
The gene for ACP was overexpressed by growing BL21(DE3) E. coli cells transformed 
with pET-28-EcACP in two liters of Terrific Broth (TB) with 50 µg/mL kanamycin at 37°C to 
mid log phase.  Gene expression was induced by addition of 0.6 mM IPTG.  The culture was 
incubated with shaking for another 4.5 h at 37°C.  Cells were then harvested by centrifugation 
and cell pellets stored at -80°C. 
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Frozen cell pellets were thawed and resuspended in 50 mM Tris pH 7.5 with 250 
units/mL benzonase and protease inhibitor cocktail pellets.  Cells were lysed by 2 passages 
through a microfluidizer with addition of lysis buffer to wash out the fluid path.  The lysate was 
centrifuged and the supernatant decanted. Ammonium sulfate was slowly added to the 
supernatant to a final concentration of 70% saturation.  The precipitated protein was removed by 
centrifugation and the resulting supernatant containing the ACP was dialyzed against 50 mM 
Tris pH 7.5 and 5% glycerol. 
Holo-ACP was generated by incubating the dialyzed ACP protein with 1 mM CoA and 
200 nM ACP Synthase in 50 mM Tris, pH 8.0, 5 mM DTT, and 10 mM MgCl2 for 2 hours at 
37°C.  To make PACP, the ACP synthase reaction was subsequently diluted 2.5-fold in 50 mM 
Tris buffer pH 8.0 with 500 µM palmitate, 10 mM MgSO4-, 10 mM ATP, 5 mM DTT, and 2.2 
µM acyl-ACP synthetase. Diluted protein was then incubated for another 4 hours at 37°C to 
produce palmitoyl-ACP. 
The palmitoyl-ACP was purified by further dilution to reduce the conductivity and run 
over a 1 mL HiTrap DEAE FF column equilibrated in 50 mM Tris, pH 7.6 and 25 mM NaCl.   
After washing with the same buffer to reach a baseline, the column was washed with 10 column 
volumes of 50 mM Tris, pH 7.6 with 50 mM NaCl.  The protein was eluted using a linear 15 
column-volume gradient from 50 mM to 190 mM NaCl.  Fractions containing the palmitoyl-
ACP were pooled and the palmitoyl-ACP confirmed by mass spectrometry. 
2.2.3 Cloning and Expression of Vibrio harveyi Acyl-ACP Synthetase 
The gene coding for soluble acyl-ACP synthetase from Vibrio harveyi [14] was 
synthesized using codons optimized for E. coli expression (GenScript) and sub-cloned for 
expression as an N-terminal His-tagged protein in pET-28b.  The protein coding sequence was 
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amplified with primers HL 238 and HL 239 (Table 2.1), while the vector was amplified with 
primers HL 221 and HL 222 (Table 2.1).  The PCR reactions, cloning, and expression were 
carried out as described above for the gene coding for ACP.  Purification was accomplished 
using nickel affinity chromatography. 
Table 2.1. Primers for Plasmid Construction. 
HL221  5’-ATGGCTGCCGCGCGG-3’ 
HL222  5’-GATCCGGCTGCTAACAAAG-3’ 
HL233  5’-GGTATATCTCCTTCTTAAAGTTAAACAAAAT-3’ 
HL234  5’-ATTTTGTTTAACTTTAAGAAGGAGATATACCATGAGCACTATC 
GAAGAACG -3’ 
HL235  5’-CTTTGTTAGCAGCCGGATCTTACGCCTGGTGGCCG-3’ 
HL238  5’-CCGCGCGGCAGCCATATGAACCAATATGTCAACGACC-3’ 
HL239  5’-CTTTGTTAGCAGCCGGATCTTACAGATGCAGTTTACGCAG-3’ 
 
2.2.4 Expression and Purification of Acetyl-CoA Carboxylase and the Isolated Components  
The plasmid pAEP3, constructed previously by Broussard et al. [3], containing the gene 
for BCCP with a His-tag on the N-terminus was transformed into E. coli BL21 (DE3) cells.  An 
overnight of this strain was used to inoculate 0.5 L LB medium in a 2 L beveled flask containing 
50 µg/mL of kanamycin. Flasks were shaken at 37°C until saturated.  Expression was then 
induced using 17.5 mM lactose and the culture shaken at room temperature for 3 hours, or 
overnight, pelleted, and frozen at -20°C. 
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 The BCCP was purified using nickel affinity chromatography. The cell pellets were first 
suspended in wash buffer (20 mM NaH2PO4, 500 mM NaCl, and 15 mM imidazole (pH 7.8)), 
then lysed by sonication and passage through a French press.  DNase was used to remove nucleic 
acids. The cell lysate was centrifuged at 17,096g for 90 min at 4°C. Pellets were discarded, and 
the supernatant was loaded onto a nickel affinity column that had been washed with 10 column 
volumes of wash buffer. Protein was eluted into 5 mL fractions using a segmented gradient 
starting with 8 column volumes of 0−10% elution buffer (20 mM NaH2PO4, 500 mM NaCl, and 
250 mM imidazole (pH 7.8)), followed by 12 column volumes of 10−100% elution buffer, 8 
column volumes of 100% elution buffer, followed by 5 column volumes of NPI-500 (20 mM 
NaH2PO4, 500 mM imidazole, 500 mM NaCl). Fractions containing BCCP were concentrated 
using Amicon Centrifugal Filters and further purified over a size exclusion column in a buffer 
containing 10 mM HEPES and 150 mM KCl (pH 7.8).  Fractions containing the pure protein 
were concentrated using Amicon centrifugal filters, aliquoted, and stored at -80°C.  
Biotin carboxylase with a His-tag on the N-terminus was purified according to Blanchard 
et al [15]. Carboxyltransferase with a His-tag on the N-terminus of the α-subunit was purified 
according to Blanchard & Waldrop [4].  The multiprotein ACC complex with a His-tag on the N-
terminus of BCCP was purified according to Broussard et al [3]. 
2.2.5 Pull Down Assays 
Pull downs targeting biotinylated BCCP used Invitrogen M-280 Streptavidin Dynabeads 
(10mg/ml). The beads (100µl) were washed 3 times with washing buffer (PBS (pH 7.4)) and 
resuspended in the same buffer.  The magnetic Streptavidin Dynabeads were separated out of 
solution with a neodymium magnet and were resuspended in 50 µl of the following solution: 10 
mM HEPES (pH 7.8) and 150 mM KCl containing 55.5 µM biotinylated BCCP.  The suspension 
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was incubated on a rotary incubator for one hour at RT. The beads were separated from the 
solution using the neodymium magnet, and the supernatant was removed. The biotinylated-
BCCP Streptavidin Dynabeads were then washed twice with washing buffer and resuspended in 
a target solution of 1.67 mM AMPPNP, 0.7 µM CT, 0.94 µM BC, 22.2 mM MgCl2, and 22.2 
mM potassium bicarbonate in 111.1 mM HEPES pH 7.8.  PACP was either omitted from the 
target solution (control), included with the target solution (0 min), or introduced 5 minutes after 
the target solution incubation began (5min).  Each of these three solutions were incubated for a 
total of 45 minutes.  The beads were washed three times with PBS before they were resuspended 
in 10 µls of Laemmli 2X sample buffer plus 20µls of PBS-0.1% Tween-20 and incubated at 80°C 
for 15 minutes. The products of the pull-downs were then stored at -20°C for Western blot 
analysis.  
2.2.6 Western Blot Analysis  
The pull-down samples were run on a 10% SDS-PAGE gel, and transferred to a PVDF 
membrane using a Bio-Rad Trans Turbo Blot system as published previously [3]. The PVDF 
membrane was incubated in blocking solution for one hour at room temperature with light 
shaking. The membrane was then incubated in a primary antibody solution containing a 1:1000 
dilution of GeneScript monoclonal mouse anti-His tag antibody in 0.1%Tween-20 PBS for one 
hour at RT with light shaking.  Thereafter, the membrane was washed three times for 10 minutes 
each with wash buffer. The membrane was then incubated in anti-mouse secondary antibody 
solution for one hour at RT with light shaking, followed by a 10-minute incubation in wash 
buffer. The membrane was then rinsed twice for 2 minutes with distilled water before adding the 
chromogenic agent. Once bands were visible, the membrane was rinsed twice for 2 minutes with 
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distilled water before it was allowed to dry. All buffers not defined, as well as the secondary 
antibody for Western development were part of Life Technologies’ Western Breeze kit. 
2.2.7 Enzymatic Assays 
The activity of the acetyl-CoA carboxylase complex [3], biotin carboxylase [15] and 
carboxyltransferase [4] were determined as previously described. All reactions were initiated by 
addition of enzyme to a 1 cm path length quartz cuvette at RT. When measuring activity of in 
vitro ACC, the reaction was initiated by adding 20 µl of the following solution: 8 µM BC, 6 µM 
CT, and 50 µM BCCP and, where indicated, 50 µM PACP in 10 mM HEPES (pH 7.8) and 150 
mM KCl. Unless otherwise noted, BC, CT, and BCCP were mixed and incubated for 5 minutes 
prior to the addition of PACP. Spectrophotometric data were collected using a Cary 60 (Agilent) 
spectrophotometer interfaced with a personal computer with a data acquisition program.  
Velocities were reported as µmol of product per minute per milligram of enzyme.  Mass of 
PACP was omitted from velocity calculations. 
2.2.8 Kinetic Analysis 
Data were analyzed by nonlinear regression using the computer programs of either 
Cleland [16] or Enzfitter. Data describing competitive inhibition were fitted to equation 1 where 
v is the initial velocity, V is the maximal velocity, A is the substrate concentration, Km is the 
Michaelis constant, I is the concentration of the inhibitor and Kis is the slope inhibition constant. 
                                             𝑣 = 	 $%&m 1+	 '(is +A                                             (1) 
 
Data describing non-competitive inhibition were fitted to equation 2 where v is the initial 
velocity, V is the maximal velocity, A is the substrate concentration, Km is the Michaelis constant, 
  57 
I is the concentration of the inhibitor and Kis is the slope inhibition constant, and Kii is the 
intercept inhibition constant.  
                                   𝑣 = 	 $%&m )*	 '(is	 *% )*	 '(ii	                                   (2) 
 
Multiple inhibition data were fitted to equation 3, where v is the initial velocity, V is the maximal 
velocity, KL and KJ are the apparent dissociation constants for the two inhibitors (L and J) and α 
is a measure of the degree of interaction of the two inhibitors [17]. 
                                   𝑣 = $)* +(L* ,(J* +,-(L(J                                          (3)  
2.3 Results 
2.3.1 Effect of Palmitoyl-ACP on ACC Activity 
The effect of PACP on the activity of ACC and the purified BC and CT enzymatic half-
reactions is shown in Figure 2.1. There was no inhibition of CT or BC activity by PACP 
confirming the findings of Davis and Cronan [5] (Figure 2.1, Blue and Green, respectively).  
Davis and Cronan, however, reported acyl-ACP inhibits ACC [5], but we did not observe 
inhibition of ACC isolated from cells as a complex (Figure 2.1, Yellow). A possible reason for 
this discrepancy may be in the preparation of the enzyme, therefore, the complex was formed in 
vitro, and tested for inhibition by PACP.  When the BC, CT, and BCCP components were mixed 
simultaneously with PACP, incubated for 5 minutes, then activity measured, there was a 15% 
decrease in activity compared to the control (Figure 2.1, Pink).  When the components of ACC 
were incubated together for five minutes prior to the addition of PACP, however, there was a 
more significant decrease (55%) in activity compared to the control, (Figure 2.1, Black), which 
was consistent with the findings of Davis and Cronan [5]. The observation of hysteresis 
prompted a further investigation into the time dependence of PACP inhibition of ACC.   
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CT + +     + + + + 
BC   + +   + + + + 
BCCP       + + + + 
ACC (in vivo)     + +     
PACP  +  +  +  +  + 
Incubated N/A N/A N/A N/A N/A N/A 0 min 0min 5min 5min 
 
Figure 2.1.  Enzymatic Activity in the Presence and Absence of Palmitoyl-Acyl Carrier Protein 
(PACP).  The activity of BC, CT, or ACC reaction in the absence of PACP was used as the 
control, and set at 100%.  A (+) symbol below the bar indicates the presence of either 8 µM BC, 
6 µM CT, 50 µM BCCP, 0.094 mg ACC, 50 µM PACP or a combination of the aforementioned 
proteins. The row labeled incubation indicates how long (in minutes) the components were 
incubated together before the addition of 50 µM PACP. N/A stands for not applicable, as in there 
was no incubation period before measuring activity.  Each measurement represents the average 
of three replicates ± the standard deviation. 
 
The time dependence for the inhibition of ACC by PACP is shown in Figure 2.2.  In this 
study, the purified components of ACC were mixed, incubated for a defined period of time (x-
axis), PACP was added, and activity was immediately measured.  At 0 and 2.5 minutes, there 
was 15% and 20% inhibition of activity, respectively. The most significant inhibition was 
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observed after a 5-minute incubation period, with a 55% decrease in ACC activity. In contrast, 
after 10 minutes, there was only a 5% decrease in activity, and after 20 minutes there was no 
inhibition.  These results show that the method by which the multiprotein complex of ACC is 
formed is critical for detecting inhibition by PACP.  In other words, once ACC formed in vitro 
had incubated for 10 min or longer, the enzyme was no longer susceptible to significant 
inhibition by PACP, similar to ACC formed in vivo. These results indicate that in the absence of 
acetyl-CoA, ACC formation exhibits a pronounced hysteresis with respect to inhibition by 
PACP. The inability of PACP to inhibit ACC after 20 min suggests that PACP may inhibit ACC 
by preventing the formation of the multiprotein complex. 
 
Figure 2.2. Time Dependence of Inhibition of Palmitoyl-Acyl Carrier Protein (PACP) on ACC. 
The initial velocity of ACC in the absence of PACP was set at 100% and used as the control. 8 
µM BC, 6 µM CT, and 50 µM BCCP, were mixed and incubated for a defined period of time (x-
axis) before addition of 50 µM PACP. Each measurement represents the average of three 
replicates ± the standard deviation. 
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2.3.2 Effect of PACP on ACC Complex Formation 
 
A pull-down assay was used to determine if PACP inhibited formation of the 
multiprotein complex of ACC (Figure 2.3).  Briefly, biotinylated BCCP was immobilized on 
Streptavidin Dynabeads and used as a target protein to bind the remaining components of ACC 
(BC and/or CT).  A control reaction in which PACP was omitted is shown in Lane 1. In Lanes 2 
and 3, PACP was either added simultaneously with the components (Lane 2), or introduced after 
a 5-minute incubation of the multiprotein complex (Lane 3). The conditions in Lane 2 are 
equivalent to Figure 2.1, Pink, while Lane 3 represents the same conditions seen in Figure 2.1, 
Black. All three components of ACC contain a His-tag, therefore, an antibody specific for a His-
tag was used to detect the proteins on a Western blot.  If PACP inhibits complex formation, then 
BCCP will be detected, but the bands representing BC and/or CT would be significantly lighter, 
or absent.  In contrast, if PACP does not inhibit complex formation, then BC, CT, and BCCP will 
all be detected on the Western blot.  The results show that there is no significant difference in the 
intensity of the bands for BC, or CT (Lanes 1-3) indicating that PACP does not inhibit formation 
of the complex. It is important to note that in a subsequent pull down assay (data not shown) a 
band for PACP was visible, indicating that PACP does bind to the multiprotein complex, but 
does not inhibit complex formation. Additionally, PACP was not shown in presented data as its 
molecular weight (~ 9 Kd) was too low. Given that PACP does not appear to inhibit ACC 
activity by abrogating multiprotein complex formation, the mechanism of inhibition was 
characterized kinetically.  
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Figure 2.3. Pull-Down Assays to Determine the Effect of Palmitoyl-Acyl Carrier Protein 
(PACP) on the Complex Formation of ACC.  Lanes 1-3 represent Streptavidin Dynabeads bound 
to biotinylated BCCP in the presence of BC and CT. Lanes 2 and 3 also included PACP 
introduced at 0 min of incubation (lane 2) and 5 min (lane 3), respectively. Lanes 4-6 are purified 
BCCP, BC, and CT, respectively.  The presence of the proteins was detected using an anti-His 
tag antibody because each protein has a His-tag on the N-terminus. 
 
2.3.3 Kinetics of PACP Inhibition  
Inhibition analyses were conducted to determine the mechanism of inhibition of PACP on 
ACC.  A noncompetitive inhibition pattern was observed when ATP, a substrate for BC, was 
varied at different fixed levels of PACP (Figure 2.4 A).  In contrast, PACP exhibited competitive 
inhibition when acetyl-CoA, a substrate for CT, was varied at different fixed levels of PACP 
(Figure 2.4 B). When the data in Figure 2.4 B were fitted to the equation for competitive 
inhibition (equation 1) an inhibition constant (Kis) of 88.0 ± 5.8 µM was calculated with a Km of 
0.44 ± 0.01 mM and a Vmax of 0.34 ± 0.01 µmol/min/mg. 
Since PACP does not inhibit either of the individual enzymatic half-reactions (BC or 
CT), PACP was expected to act as an allosteric inhibitor of ACC and exhibit either 
noncompetitive, or uncompetitive inhibition, as was the case versus ATP.  The competitive 
inhibition pattern versus acetyl-CoA suggests that an alternative mechanism of inhibition may be 
No PACP PACP 0 min PACP 5 min BCCP BC CT 
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partial competitive inhibition where the inhibitor and substrate bind at different sites.  The 
turnover of the ES and EIS complexes would occur at the same rate, while the affinity of 
substrate for E and EI is affected.  It is important to note that Davis and Cronan found that 
activity of ACC was never completely abolished by acyl-ACP [5], which is consistent with a 
partial competitive inhibition mechanism.  
To confirm PACP binds allosterically to ACC a multiple inhibition analysis was 
conducted.  Briefly, multiple inhibition studies are carried out by determining the initial velocity 
at increasing concentrations of one inhibitor while the second inhibitor is held constant [17].  The 
substrate concentrations are held constant at sub-saturating levels, which allows both inhibitors 
to bind to the enzyme.  In the case of ACC, the initial velocity was measured as a function of 
increasing amounts of malonyl-CoA, a product inhibitor of ACC, at fixed increasing levels of 
PACP (Figure 2.4 C), while the substrates ATP and acetyl-CoA were held at sub-saturating 
levels.  When the data were plotted as a Dixon plot an intersecting pattern was observed, 
indicating that malonyl-CoA and PACP can bind simultaneously.  In other words, the binding 
sites for PACP and malonyl-CoA are topologically distinct.  These results are consistent with 
Figure 2.1, Blue, and confirm that PACP does not bind in the active site of CT, but inhibits ACC 
allosterically.  This result is also consistent with a mechanism of partial competitive inhibition.  
Furthermore, when the data in Figure 2.4 C were fitted to Equation 3, an α value of 1.5 was 
calculated.  The α value in equation 3 is an indication of the interaction between the two 
inhibitors, where a value greater than 1 signifies an antagonistic effect.  An α value of 1 would 
indicate no interaction between the inhibitors, while an α value less than 1 would indicate 
synergism in the binding of the inhibitors [17].   Thus, the fact that PACP and malonyl-CoA 
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interact antagonistically suggests that PACP interferes with the second half-reaction which is 
catalyzed by CT. 
A.   
  
B.  
 
C.  
  
Figure 2.4. Inhibition of ACC. A. Inhibition by palmitoyl-acyl carrier protein (PACP) at 0 µM 
(u), 30 µM (n), and 50 µM (l) while varying ATP and holding acetyl-CoA constant at 0.5 
mM.  Points represent observed velocities, while lines represent best fit of the data to equation 2.  
B. Inhibition by PACP at 0 µM (u), 30 µM (n), and 50 µM (l) while varying acetyl-CoA and 
holding ATP constant at 0.2 mM.  Points represent observed velocities, while lines represent best 
fit of the data to equation 1.  C. Multiple inhibition of ACC in the presence of PACP. Malonyl-
CoA was used as a product inhibitor, and was varied at fixed levels of PACP at 0 µM (u), 50 
µM (n), and 70 µM (l). The points represent observed velocities, while the lines represent best 
fit of the data to equation 3.   
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Given that ACC forms a multiprotein complex that is required for catalysis [3], we 
investigated the possibility that PACP may hinder the communication between the two active 
sites of BC and CT. For this study, the stable complex of CT-BCCP was prepared in vitro in the 
same manner as in vitro ACC as previously published [3]. The concentration of the BC 
component was varied in the presence and absence of PACP, while the substrates ATP and 
acetyl-CoA were held at sub-saturating levels.  As shown in Figure 2.5 A, a noncompetitive 
inhibition pattern was observed, which is congruous with the fact that PACP is noncompetitive 
with respect to ATP (Figure 2.4 A).  In contrast, when the purified BC-BCCP complex was held 
constant, and the concentration of the CT was varied at different fixed levels of PACP, a 
competitive inhibition pattern was observed (Figure 2.5 B).  This is consistent with PACP acting 
as a competitive inhibitor with respect to acetyl-CoA (Figure 2.4 B).  These results suggest that 
PACP hinders the productive binding of CT to the BC-BCCP complex.  
2.3.4 Structure Activity Analysis of PACP Inhibition on ACC 
A structure function analysis was carried out in order to determine which moiety of 
PACP is responsible for the inhibitory effect on ACC.  Palmitoyl-ACP is composed of three 
distinct chemical components: (1) the acyl carrier protein (apo-ACP), (2) a pantothenic acid arm 
and (3) palmitic acid.  These three components, plus ACP modified with the pantothenic acid 
arm (holo-ACP) were tested for their ability to inhibit ACC activity.  For these studies, the 
purified components of ACC were mixed in the presence and absence of one of these four 
potential inhibitors.  The ACC components BC, CT, and BCCP were incubated together for five 
minutes prior to the addition of the inhibitor as described in Figure 2.1.  As shown in Figure 2.6 
A, apo-ACP (Pink), holo-ACP (Green) and palmitic acid (Yellow) had no inhibitory effect. The 
absence of inhibition by holo-ACP is consistent with Davis and Cronan who reported that holo-
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ACP did not inhibit ACC [5].  Surprisingly, pantothenic acid (Figure 2.6 A, Black) significantly 
inhibited ACC (58%), suggesting that pantothenic acid is the moiety of PACP that is responsible 
for inhibition of ACC.  
A.  
 
B.  
               
Figure 2.5. Inhibition by Palmitoyl-Acyl Carrier Protein (PACP) on ACC Component 
Interaction. A. CT-BCCP complex was held constant while varying BC at 0 µM (u), 30 µM 
(n), and 50 µM (l) PACP.  Points represent observed velocities, while lines represent best fit of 
the data to equation 2. B. BC-BCCP complex was held constant while varying CT at 0 µM (u), 
50 µM (n), and 60 µM (l) PACP. Points represent observed velocities, while lines represent 
best fit of the data to equation 1. 
 
To determine if ACC formation exhibits hysteresis in the presence of pantothenic acid, 
the time dependence of inhibition was examined (Figure 2.6 B).  The purified components of 
ACC (BC, BCCP, and CT) were mixed and incubated for 0, 5, or 20 minutes, pantothenic acid 
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was added, and activity was measured. At 0, 5, and 20 minutes pantothenic acid exhibited 23%, 
58%, and 3% inhibition compared to the control, respectively.  Thus, pantothenic acid exhibited 
a time-dependent inhibition pattern similar to that of PACP (Figure 2.2).   
A.  
 
B.  
 
Figure 2.6. A.  Inhibition of ACC by the Chemical Components of Palmitoyl-Acyl Carrier 
Protein (PACP).  The activity of ACC in the absence of inhibitor was used as the control, and set 
at 100%.   Each reaction contained 8 µM BC, 6 µM CT, and 50 µM BCCP, and 50 µM of the 
chemical component indicated, which was added after the components of ACC were incubated 
together for 5 minutes. Each measurement represents the average of three replicates ± the 
standard deviation. B. Time dependence of inhibition of pantothenic acid on ACC. The initial 
velocity of ACC in the absence of pantothenic acid was set at 100% and used as the control.  The 
components of ACC were mixed and incubated for a defined period of time (x-axis) before 
addition of pantothenic acid.  Each measurement represents the average of three replicates ± the 
standard deviation. 
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Interestingly, pantothenic acid still inhibited after 20 minutes, unlike PACP, indicating 
that pantothenic acid may be a better inhibitor than PACP.  Therefore, both the type and degree 
of inhibition of ACC by pantothenic acid was examined. A noncompetitive inhibition pattern 
was observed when ATP was varied at different fixed levels of pantothenic acid (data not 
shown), while a competitive inhibition pattern was observed, when acetyl-CoA was varied at 
different fixed levels of pantothenic acid (Figure 2.7 A). These inhibition patterns for 
pantothenic acid were in agreement with the inhibition patterns exhibited by PACP (Figures 2.4 
A and 2.4 B).  When the data in Figure 2.7 A were fitted to equation (1) an inhibition constant of 
43.9 ± 6.3 µM was calculated, with a Km of 0.26 ± 0.02 mM and a Vmax of 0.065 ± 0.002 
µmol/min/mg, confirming that pantothenic acid is a more potent inhibitor of ACC than PACP.    
To determine if pantothenic acid binds to ACC allosterically, analogous to PACP, a 
multiple inhibition analysis was performed.  The initial velocity of ACC was measured by 
varying the product inhibitor, malonyl-CoA, at different fixed levels of pantothenic acid, while 
ATP and acetyl-CoA were held constant at sub-saturating levels. When the data were plotted as a 
Dixon plot an intersecting pattern was observed (Figure 2.7 B), indicating that malonyl-CoA and 
pantothenic acid can bind simultaneously.  These results are consistent with the multiple 
inhibition analysis for PACP and confirm that pantothenic acid also does not bind in the active 
site of CT, but inhibits allosterically.  When the data in Figure 2.7 B were fitted to Equation 3, an 
α value of 2.4 was calculated, indicating a larger antagonistic effect than observed with PACP. 
These results suggest that pantothenic acid is both the inhibitory moiety of PACP as well as a 
more potent inhibitor of ACC. 
 
 
  68 
A.  
  
B.  
 
 
 
 
 
Figure 2.7. A. Inhibition of ACC.  Inhibition by pantothenic acid at 0 µM (u), 30 µM (n), and 
50 µM (l) while varying acetyl-CoA and holding ATP constant at 0.2 mM. Points represent 
observed velocities, while lines represent best fit of the data to equation 1. B. Multiple inhibition 
of ACC in the presence of pantothenic acid and malonyl-CoA. Malonyl-CoA was used as a 
product inhibitor, and varied at fixed levels of pantothenic acid at 0 µM (n), 50 µM (u), and 70 
µM (l). The points represent observed velocities, while the lines represent best fit of the data to 
equation 3.  
 
2.4 Discussion 
2.4.1 Hysteresis and Enzymology 
 The term hysteresis was first defined in physics to describe a physical phenomenon in 
which a lag, or delay is observed.  In 1970 Carl Frieden introduced this term to enzymology after 
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he discerned that some regulatory enzymes exhibit a delay in activity in response to a change in 
metabolite concentration [18]. For example, glycogen phosphorylase exhibits a hysteretic 
interconversion between an inactive tetramer and an active dimer in response to glycogen [18, 
19].  Prior to Frieden’s study, researchers failed to note the correlation between time dependent 
enzymes and metabolic regulation.  However, Frieden determined hysteresis was not just a 
random phenomenon, but a way for the cell to exercise increased control over metabolite 
production [20, 21]. 
2.4.2 Hysteresis of Acetyl-CoA Carboxylase  
 We propose that the hysteretic behavior of ACC may play a key role in the regulation of 
the flux through FAS.  Specifically, when large quantities of the end product PACP accumulate 
quickly, and are quickly processed, the hysteresis prevents an instantaneous down regulation of 
fatty acid synthesis.  Thus, fatty acid production can continue at its normal rate, obviating 
dramatic oscillations in the levels of FAS intermediates.   
The significance of limiting these oscillations becomes apparent when considering other 
metabolic pathways in which FAS intermediates play a key role. For example, FAS also supplies 
the building blocks for the synthesis of lipoic acid and biotin, of which the initial substrates are 
octanoic acid and malonyl-CoA, respectively.  Due to the hysteresis, flux through the lipoic acid 
and biotin synthetic pathways would remain unaffected by sudden changes in the level of acyl-
ACP.   
Acetyl-CoA carboxylase is not the only enzyme in FAS inhibited by acyl-ACP.  In fact, 
FabH, which catalyzes the condensation of acetyl-CoA with the growing acyl chain, and FabI, 
which catalyzes the reduction of the intermediate double bond in the acyl chain are also inhibited 
by acyl-ACP [22].  Interestingly, FabH and FabI have not been found to exhibit hysteresis in 
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response to acyl-ACPs. Activity for both enzymes was measured using fixed-time assays with a 
single time point, however, which may have masked any hysteretic behavior [22]. More likely, 
as acyl-ACPs are a substrate for FabH and a product of FabI, the mechanism of inhibition is 
either substrate or product inhibition, respectively, and most likely would not exhibit hysteresis.  
This differs significantly from the inhibition of ACC by PACP, where the data strongly suggest 
that inhibition is hysteretic, as well as allosteric.  
2.4.3 Mechanism of Inhibition  
 The inhibition of ACC by PACP clearly occurs via an allosteric mechanism. Although 
inhibition studies suggested PACP and acetyl-CoA compete for the same binding site, more 
rigorous studies (multiple inhibition, Figure 2.4 C) demonstrated that PACP and acetyl-CoA bind 
in separate locations in an antagonistic manner.  This is consistent with the observation that 
PACP interferes with the productive binding of CT with the BC-BCCP complex (Figure 2.5 B). 
A possible model to explain this phenomenon is shown in Figure 2.8. Figure 2.8 
illustrates the relationship between the change in conformation of ACC in the absence of 
substrate, and the binding of PACP.  The data suggest there is a finite period of time in which 
PACP can inhibit ACC, indicating that ACC undergoes a slow isomerization beginning when 
CT, BCCP, and BC are first combined.  This initial interaction is shown as Eo.  A slow (5-
minute) isomerization occurs to give E*, creating a binding site for PACP (I) forming EI*.  After 
this finite period passes (10 minutes or more), or if there is a large concentration of acetyl-CoA, 
ACC assumes a conformation (E′) that eliminates the binding site for PACP, thereby preventing 
the inhibition of ACC by PACP.  The E′ complex is analogous to ACC purified from cells after 
forming in vivo.  
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This mechanism of allosteric inhibition of ACC by PACP can be compared to the 
inhibition of protein kinase Bα (PKBα) by AKT inhibitor VIII [23].  Protein kinase Bα can be 
found in either an active or inactive conformation.  The inactive conformation creates a binding 
site for AKT inhibitor VIII which, upon binding, locks the enzyme into an inactive state.  
Conversely, in the active conformation the AKT inhibitor VIII binding site is not present 
resulting in no inhibition. Similarly, ACC may create a binding site for PACP that is only present 
whilst ACC is isomerizing. 
                             
Figure 2.8. Model Depicting the Relationship Between the Change in Conformation of ACC in 
the Absence of Substrate, and the Binding of PACP.  Eo represents the conformation of the ACC 
components immediately after mixing. E* represents the conformation of the ACC components 
after a 5-minute incubation period, in which the inhibitor may bind to form EI*.  E ′ represents 
the conformation of ACC when the components have incubated for 10 minutes or more.  
 
The inhibition of ACC by PACP provides insight into the state of ACC in vivo. Based on 
the data presented here, it follows that in order for PACP to act as a metabolic regulator, the 
formation of the ACC complex must be in flux. For example, if the ACC multiprotein complex is 
continually forming, and dissociating, then PACP would continually have a target for inhibition.  
The half-life of ACC has not been reported, however, proteins with a regulatory role generally 
have short half-lives.  Since ACC catalyzes the rate-determining and regulated step in fatty acid 
synthesis in bacteria [24], the turnover of acetyl-CoA carboxylase is likely to occur regularly 
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presenting a continuous target for inhibition by PACP.  Further evidence that the results reported 
here are relevant in vivo are the endogenous level of acetyl-CoA in E. coli in the growth phase 
(which is when palmitoyl-ACP would be produced) is 0.6 mM [13] This level of acetyl-CoA is 
in the mid-range of concentrations used in Figure 2.4, showing that acetyl-CoA reverses the 
inhibition by PACP.  Moreover, the inhibition constant for PACP (~88 µM) is close to the 
endogenous level of ACP (~ 100 µM) [25].  Since neither apo-ACP nor holo-ACP inhibit ACC, 
this means that ACC (and by inference FAS) would only be inhibited when the majority of the 
ACP has been acylated.  If the inhibition constant for PACP were lower (i.e. palmitoyl-ACP 
bound to ACC more tightly) this would mean only a small amount of palmitoyl-ACP would be 
required to inhibit ACC, which would be deleterious to cell growth. Thus, the kinetic results 
observed in vitro are consistent with the in vivo levels of substrate and inhibitor.    
2.4.4 Structure-Activity Relationships 
The structure-activity studies clearly indicate that the pantothenic acid moiety of PACP is 
responsible for the inhibition of ACC, which explains why apo-ACP (ACP without pantothenic 
acid) has no effect on ACC.  What is not clear, however, is why acyl-ACP and pantothenic acid 
inhibit ACC, but holo-ACP, which also contains the pantothenic acid component, does not.  A 
possible mechanism for inhibition can be gleaned by comparing the three-dimensional structures 
of ACPs bound to LpxD acyl transferase [26] versus unbound acyl-ACP [26]. LpxD is an 
enzyme that transfers the acyl group from acyl-ACP to the amino group of UDP-3-O-
(hydroxytetradecanoyl) glucosamine during Lipid A synthesis in Gram-negative bacteria.  The 
crystal structure of unbound acyl-ACP from E. coli (Figure 2.9 A) shows the four helices create a 
hydrophobic pocket (Pink) that surrounds the growing acyl chain (Black) with the pantothenic 
acid arm (Yellow) close to the protein [26].  In contrast, the crystal structure of LpxD bound to 
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acyl-ACP (Figure 2.9 B), shows that the acyl chain (Black) is no longer in the hydrophobic 
pocket of ACP (Pink) but is inserted into the active site of the enzyme (Light Blue), causing the 
pantothenic arm (Yellow) to become straight [26]. This translocation exposes pantothenic acid to 
interactions with the catalytic residues of LpxD, shown in Red. Conversely, the crystal structure 
of LpxD bound to holo-ACP (Figure 2.9 C) shows the pantothenic arm (Yellow) is not extended 
towards the catalytic residues (Red) of the enzyme (Light Blue), but is curled up towards ACP 
(Pink), preventing or minimizing the interactions of the catalytic residues (Red) of LpxD (Light 
Blue) with the pantothenic arm [26].  Consistent with this proposed mechanism is that in 
unbound holo-ACP the position of pantothenic acid is highly variable [27]. Therefore, the 
interaction of acyl-ACP and holo-ACP with ACC may be similar to that of LpxD, which may 
explain why holo-ACP is unable to inhibit ACC. 
2.5 Conclusions  
This report shows two major findings. First, the flux through FAS is more tightly 
regulated than previously reported. Specifically, the marked hysteresis of ACC negates 
deleterious effects of oscillations in FAS metabolites when inhibited by PACP.  Second, the 
novel finding that pantothenic acid is the moiety of PACP that inhibits ACC with a micromolar 
Kis.  Thus, pantothenic acid can lead to a scaffold for developing allosteric inhibitors of the 
enzyme which could serve as new antibacterial agents.  Both catalytic functions of ACC, biotin 
carboxylase and carboxyltransferase, have been validated as targets for antibacterial 
development [28].  Antibacterial agents, to date, targeting biotin carboxylase and 
carboxyltransferase bind in the active site.  In contrast, the allosteric inhibition of ACC by 
pantothenic acid suggests an unforeseen binding site in the multiprotein complex that can be 
targeted to design inhibitors with antibacterial activity.  
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A.  
                                                     
B.  
                           
 
C.  
                      
 
Figure 2.9. Three-Dimensional Structures of Various Forms of ACP. A. Three-dimensional 
structure of unbound acyl-ACP (ACP is pink, pantothenic acid is yellow, acyl chain is black) 
(PDB: 1lOI).  B. Three-dimensional structure of acyl-ACP (ACP is pink, pantothenic acid arm is 
yellow, acyl chain is black, catalytic residues are red), in complex with LpxD (light blue) (PDB: 
4IHF). C. Three-dimensional structure of holo-ACP (ACP is pink, pantothenic acid arm is 
yellow, catalytic residues are red) in complex with LpxD (light blue) (PDB: 4IHH).  
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CHAPTER 3. THE ROLE OF THE N-TERMINAL DOMAIN OF BIOTIN 
CARBOXYL CARRIER PROTEIN IN CATALYSIS BY BACTERIAL 
ACETYL-COA CARBOXYLASE  
 
3.1 Introduction  
            Acetyl-CoA carboxylase (ACC) catalyzes the first committed and regulated step of fatty 
acid synthesis in all animals, plants, and bacteria [1]. The reaction catalyzed by ACC occurs via 
two half-reactions (Scheme 3.1). 
 
Scheme 3.1. 
 In the first half-reaction, the vitamin biotin, which is covalently linked to the biotin carboxyl 
carrier protein (BCCP), undergoes an ATP-dependent carboxylation catalyzed by biotin 
carboxylase (BC). In the second half-reaction, the carboxyl group is transferred from biotin to 
acetyl-CoA by carboxyltransferase (CT) forming malonyl-CoA.  
            Though the function of ACC in all animals, plants, and bacteria is the same, the structures 
of ACC differ greatly between organisms. In bacteria, catalysis by ACC requires formation of a 
macromolecular complex composed of three separate subunits (BC, CT, and BCCP) [2], though 
BC and CT retain their activity when purified separately [1].   Alternatively, in most eukaryotes 
ACC is a single polypeptide chain where the three proteins (BC, CT and BCCP) are organized 
into domains [3]. Though the BC and CT subunits in bacterial ACC mimic the BC and CT 
domains in eukaryotes [4, 5, 6, 7], the BCCP subunit in bacteria differs significantly from the 
BCCP domain in eukaryotes.   
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            Bacterial BCCP contains two domains [1] connected by a proline/alanine rich linker [8].  
These domains in E. coli are referred to as the N-terminal domain (NTD), composed of residues 
1-71, and the C-terminal domain, which will be referred to hereafter as the biotinyl domain (BD), 
and is composed of residues 77-156. While both NTD and the BD have been shown to affect 
catalysis of ACC [2, 9], only the role of the BD in catalysis of ACC has been determined. In this 
report, the role of NTD in the catalytic mechanism of ACC has been investigated.     
3.2 Materials and Methods 
3.2.1 Reagents  
Amicon Ultracentrifugal Filters (molecular mass cut off of 3,000, 10,000 and 50,000 
kDa) were from Millipore. Beads with a His-tag covalently linked were obtained from 
Invitrogen. The Bradford Protein assay reagent, the plasmids pET28b+ and pCDF-Duet were 
purchased from Novagen. Kanamycin, ampicillin, streptomycin, isopropyl β-D-1-
thiogalactopyranoside (IPTG), D-Lactose and PINKstain Protein Ladder were obtained from 
Gold Biotechnology. Casamino acids were from Lab Scientific. NdeI, HindIII, and BamHI were 
from New England BioLabs. The HiLoad 16/60 Superdex 200 prep-grade gel filtration column 
and HisTrap HP Ni Sepharose was purchased from GE Healthcare. Ni-NTA agarose was 
acquired from Qiagen. All other reagents were purchased from Sigma Aldrich.   
3.2.2 Cloning of the Biotinyl Domain of Biotin Carboxyl Carrier Protein 
The gene coding for the BD (the last 87 residues of BCCP) was generated by PCR using 
primers BCCP875 and 2AEPBCCP2 (Table 3.1) and the plasmid pYML11 [2], which contains 
the gene for full-length BCCP. The PCR product was inserted into pET28b+ between NdeI and 
BamHI to create pEMP3.  
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Table 3.1. Primers for Plasmid Construction. 
Protein Primer Name Primer       
5’-3’ 
THNS THNSForward CTTCTTGGATCCGATGACCACTCTGTGCCGC 
THNS THNSReverse CTTCTTAAGCTTTCATTAATCGGCGGTCTG 
BD BCCP875 CTTCTTCATATGGAAGCGGCCAGCAGCAGCG 
BD/NTD 2AEPBCCP2 CTTCTTGGATCCACCTCCTTACTCGATGACGACCAG 
CGCGCTC 
NTD 2AEPBCCP1  CTTCTTCATATGGATATTCGTAAGATTAAAAAA 
 
3.2.3 Cloning of the N-terminal domain of Biotin Carboxyl Carrier Protein 
The gene coding for NTD (the first 77 residues of BCCP) was generated by PCR using 
primers 2AEPBCCP1 and 2AEPBCCP2 (Table 3.1) and the plasmid pYML11 [2] which 
contains the gene for full-length BCCP. The PCR product was then inserted into pET28b+ 
between NdeI and BamHI to create pAEP5.  
3.2.4 Cloning of 1,3,6,8-Tetrahydroxynapthalene Synthase (THNS) 
The plasmid containing the gene coding for THNS was a gift from OPX Biotechnologies, 
Boulder, CO. The gene was amplified by PCR using primers THNSForward and THNSReverse 
(Table 3.1). The PCR product was inserted into pCDFDuet-1 between BamHI and HindIII to 
create pAER1.  
3.2.5 Purification of the N- and C-Terminal Domains of Biotin Carboxyl Carrier Protein 
The plasmid coding for the BD (pEMP3) was transformed into E. coli BL21 (DE3). An 
overnight of that strain was then used to inoculate 0.5 L LB medium in a 2 L beveled flask, 
which contained 50 µg kanamycin. Cultures were incubated at 37° C until an OD600 of 0.6. The 
cultures were cooled to room temperature and expression induced using 250 µM IPTG.  The 
cultures were incubated with shaking for an additional 3 hours. The cells were pelleted, and then 
frozen at -20° C. 
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The cell pellets were thawed and resuspended in buffer (20 mM NaH2PO4, 500 mM 
NaCl, and 15 mM imidazole (pH 7.8)), then sonicated and passed through a French press to lyse 
the cells.  DNase was used to remove nucleic acids and the cell lysate was centrifuged at 17,096g 
for 60 min at 4° C, the pellets were discarded. The supernatant was loaded onto a nickel affinity 
column that had been washed with 10 column volumes of buffer (20 mM NaH2PO4, 500 mM 
NaCl, and 15 mM imidazole (pH 7.8)). Protein was eluted into 5 mL fractions using a segmented 
gradient starting with 8 column volumes of 0−10% elution buffer (20 mM NaH2PO4, 500 mM 
NaCl, and 250 mM imidazole (pH 7.8)), then by 12 column volumes of 10−100% elution buffer, 
8 column volumes of 100% elution buffer, followed by 5 column volumes of NPI-500 (20 mM 
NaH2PO4, 500 mM imidazole, 500 mM NaCl). Fractions containing the BD were concentrated 
using Amicon Centrifugal Filters and purified over a size exclusion column in a buffer 
containing 10 mM HEPES and 150 mM KCl (pH 7.8).  Fractions containing the pure protein 
were concentrated using Amicon Centrifugal Filters, aliquoted, and stored at -80° C.  The gene 
coding for NTD was overexpressed and the protein was purified in the same manner as described 
above for the BD, except the plasmid, pAEP5, was used in place of pEMP3.  
3.2.6 Purification of Biotin Carboxylase, Carboxyltransferase and Biotin Carboxyl Carrier 
Protein  
Biotin carboxylase with a His-tag on the N-terminus was purified according to Blanchard 
et al. [10]. Carboxyltransferase with a His-tag on the N-terminus of the α-subunit was purified 
according to Blanchard & Waldrop [11].  BCCP with a His-tag on the N-terminus was purified 
according to Evans et al. [12]. 
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3.2.7 Purification of 1,3,6,8-Tetrahydroxynapthalene Synthase (THNS).  
The plasmid pAER1 was transformed into E. coli BL21 (DE3) cells. An overnight of this 
strain was used to inoculate 0.5 L LB medium in a 2 L beveled flask, which contained 50 µg 
streptomycin.  Cultures were incubated at 37° C until an OD600 of 0.6. The cultures were cooled 
to room temperature and expression induced using 250 µM IPTG.  The cultures were incubated 
with shaking for an additional 3-5 hours. The cells were pelleted, and then frozen at -20° C. The 
cell pellets were suspended in buffer (20 mM NaH2PO4, 500 mM NaCl, and 15 mM imidazole 
(pH 7.8)), then lysed by sonication and passage through a French press.  DNase was used to 
remove nucleic acids. The cell lysate was centrifuged at 17,096g for 60 min at 4° C.  The 
supernatant was loaded onto a nickel affinity column that had been washed with 10 column 
volumes of buffer (20 mM NaH2PO4, 500 mM NaCl, and 15 mM imidazole (pH 7.8)). Protein 
was eluted into 5 mL fractions using a segmented gradient starting with 8 column volumes of 
0−10% elution buffer (20 mM NaH2PO4, 500 mM NaCl, and 250 mM imidazole (pH 7.8)), then 
by 12 column volumes of 10−100% elution buffer, and lastly, 8 column volumes of 100% 
elution buffer.  
Fractions containing THNS were concentrated using Amicon Centrifugal Filters and 
purified over a size exclusion column in a buffer containing 10 mM HEPES and 150 mM KCl 
(pH 7.8).  Fractions containing the pure protein were concentrated using Amicon Centrifugal 
Filters, aliquoted, and stored at -80° C. 
3.2.8 In vivo Purification of the Acetyl-CoA Carboxylase Complex in the Absence of the N-
terminal Domain of Biotin Carboxyl Carrier Protein 
The plasmid coding for the BD (pEMP3) was transformed into E. coli BL21 (DE3). An 
overnight of that strain was then used to inoculate 1 L LB medium in a 2 L beveled flask, which 
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contained 100 µg kanamycin. Cultures were incubated at 37° C until saturated. The cultures were 
cooled to room temperature and expression induced using 500 µM of IPTG.  The cultures were 
incubated with shaking overnight. The cells were pelleted and then frozen at -20° C. 
The cell pellets were thawed and resuspended in buffer (20 mM NaH2PO4, 500 mM 
NaCl, and 15 mM imidazole (pH 7.8)), then sonicated and passed through a French press to lyse 
the cells.  DNase was used to remove nucleic acids and the cell lysate was centrifuged at 17,096g 
for 60 min at 4° C, and the pellets were discarded.  The supernatant was loaded onto a nickel 
affinity column that had been washed with 10 column volumes of buffer (20 mM NaH2PO4, 500 
mM NaCl, and 15 mM imidazole (pH 7.8)). Protein was eluted into 5 mL fractions using a 
segmented gradient starting with 8 column volumes of 0−10% elution buffer (20 mM NaH2PO4, 
500 mM NaCl, and 250 mM imidazole (pH 7.8)), then by 12 column volumes of 10−100% 
elution buffer, and finally by 8 column volumes of 100% elution buffer. Fractions containing the 
complex were pooled and concentrated using dialysis tubing with a MWCO of 3K kDa and 
allowed to dehydrate in polyvinylpyrrolidone.  Fractions containing the pure complex were run 
on a 15% SDS-PAGE gel. 
3.2.9 Pull-Down Assays Targeting the N-terminal Domain of Biotin Carboxyl Carrier Protein 
and Full-Length Biotin Carboxyl Carrier Protein 
Pull downs targeting NTD or the full-length BCCP utilized biotin agarose resin.  The 
resin (500 µl) was aliquoted into a 1.5 mL micro centrifuge tube, and pelleted at 14,549g. The 
supernatant was removed, and the resin was rinsed with 0.5 ml PBS (pH 7.4). This process was 
repeated twice. The resin was then resuspended in 50 µl of a solution (10 mM HEPES (pH 7.8) 
and 150 mM KCl) containing 10.4 µM NTD, or 20 µM full-length BCCP. The suspension was 
then incubated on a rotary incubator for two hours at room temperature. The resin was then 
pelleted at 14,549g. and the supernatant removed. The resin was washed 3 times, resuspended in 
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30 µl of 25 mM biotin (pH 7.9) and incubated on a rotary shaker for 2 hours at 37° C. The 
supernatant was run on a 15% SDS-PAGE gel.  
3.2.10 Steady-State Kinetic Assays  
The activity of biotin carboxylase [10], acetyl-CoA carboxylase complex [2], ACC 
complex lacking the NTD, and the reconstituted ACC complex (which contains BD and NTD 
purified separately and then combined) were all determined by following the production of ADP 
using a coupled enzyme assay with pyruvate kinase and lactate dehydrogenase as previously 
described [2, 10].  The activity of carboxyltransferase was determined using a coupled enzyme 
assay as previously described [11].  Initial velocities were measured using a Cary 60 (Agilent) 
spectrophotometer interfaced with a personal computer with a data acquisition program.  
Velocities were reported as µmol of product per minute per milligram of the non-varied protein. 
3.2.11 Measurement of Malonyl-CoA Production using THNS 
 To determine malonyl-CoA production in the presence and absence of the N-terminal 
domain the following components were mixed: 8 µM BC, 6 µM CT, 1 mM acetyl-CoA, 0.4 mM 
ATP, 37.1 µM of THNS, and 50 µM of either full-length BCCP, the BD, or reconstituted BCCP 
(the BD and NTD combined) in 10 mM HEPES (pH 7.8) and 150 mM KCl. It is important to 
note the enzyme THNS catalyzes the cyclization of malonyl-CoA to form 
tetrahydroxynapthalene, or THN.  Under oxidizing conditions, THN spontaneously converts into 
flaviolin, which absorbs at 340 nm. It has been shown that THN converts to flaviolin over a 6-
hour period [13]. Thus, the absorbance of the mixture was measured at 340 nm upon addition of 
THNS, and again after 6 hours. All experiments were done in triplicate.  
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3.2.12 Determining Malonyl-CoA Production in a Single Turnover of Acetyl-CoA Carboxylase 
Invitrogen His-Tag Dynabeads (180µl) were washed 3 times with PBS (pH 7.4) and then 
resuspended in a 100 µL solution of BC (47.6 µM) and a solution of either 100 µL of BCCP (56 
µM), or 150 µL BD (125 µM), or reconstituted BCCP (150 µM BD and 25 µL of NTD (240 
µM)). The proteins were allowed to attach to the beads for 30 minutes on a rotary shaker at room 
temperature, then 0.4 mM ATP was added and the suspension incubated on a rotary shaker for 
10 minutes at room temperature.   The beads were then separated out of solution with a 
neodymium magnet and washed with PBS (pH 7.4) three times. The beads were suspended in 50 
µL of CT (10 µM) and 200 µL acetyl-CoA (20 mM) and allowed to incubate on a rotary shaker 
for 10 min at room temperature. The beads were next separated out of solution using a 
neodymium magnet, and the supernatant transferred to a 1 cm path length quartz cuvette. Finally, 
200 µL of THNS (37.1 µM) was added, the reaction mixed and incubated for 10 min. at which 
point the absorbance at 340 nm was measured.  After a 6-hour incubation [13], the absorbance at 
340 nm was measured again.  All experiments were done in triplicate.  
3.2.13 Kinetic Analysis 
Data were analyzed by nonlinear regression using the computer programs of Cleland 
[14]. Data describing competitive inhibition were fitted to equation 1 where v is the initial 
velocity, V is the maximal velocity, A is the substrate concentration, Km is the Michaelis 
constant, I is the concentration of the inhibitor and Ki is the inhibition constant. 
                                             𝑣 = 	 $%&m 1+	 '(i +A                                             (1) 
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3.2.14 Secondary Structure and Disorder Prediction 
Secondary structure prediction was conducted with PSIPRED 4.0 [15]. Four different 
methods have been used to predict disordered regions in BCCP, DISOPRED3 [16], IUPred [17], 
disEMBL 1.5 [18], and prDOS [19]. 
3.3 Results 
3.3.1 The Role of the N-terminal Domain (NTD) in Complex Formation. 
            Previous studies have shown that bacterial ACC forms a complex of the subunits BC, CT, 
and BCCP [2]. To determine if the NTD plays a role in the formation of the ACC complex, NTD 
was deleted, and the gene for isolated BD with a His-tag on the N-terminus was overexpressed 
extragenomically. If the NTD is not required for complex formation, then when the BD is 
purified by nickel-affinity chromatography it will pull-down the endogenous BC and CT 
subunits.  As shown in Figure 3.1, Lane 1, BC, CT, and the BD are present indicating formation 
of the macromolecular complex. It is interesting to note there is also a faint band representing 
full-length BCCP. This is most likely due to the fact that the complex requires more than one 
BCCP protein to form [20], thus endogenously expressed BCCP was also incorporated into the 
macromolecular complex. These results suggest NTD is not required for ACC complex 
formation.      
3.3.2 The Effect of NTD on Enzymatic Activity 
            As NTD is not required for the formation of the macromolecular complex of ACC, the 
role of NTD must be catalytic.  The effect of the NTD on the half-reactions (Scheme 3.1) 
catalyzed by the isolated subunits, BC (reaction 1) and CT (reaction 2) was examined first.  
Figure 3.2 A shows the effect of the NTD on the reaction catalyzed by BC.  It is important to 
note isolated BC exhibits a slow bicarbonate-dependent ATPase reaction in the absence of biotin 
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[10].  Thus, the ATPase activity of BC in the absence of biotin was measured and set to 100% 
(Figure 3.2 A, Black).  When measuring the activity of BC in the presence of BCCP, the ATPase 
activity was zero (Figure 3.2 A, Stripes), consistent with previous studies [2].  In contrast, the 
BD increased the ATPase activity 182% (Figure 3.2 A, Dots) compared to BC alone, which is 
also consistent with previous studies [9].  When the two domains of BCCP are combined 
(heretofore referred to as reconstituted BCCP), the activity is only 9% higher relative to BC 
alone (Figure 3.2 A, Squares). In other words, when BD and NTD were combined, the negative 
effect on catalysis was similar to that of full-length BCCP. These results indicate that NTD 
modulates the activity of the BC subunit. 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Formation of the Macromolecular Complex of ACC sans NTD in vivo. Lane 1, 
Overexpression of the biotinyl domain bound to BC and CT. Lane 2, Molecular weight markers. 
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            The effect of NTD on the reaction catalyzed by CT is shown in Figure 3.2 B. The CT 
half-reaction is run in the non-physiological direction where malonyl-CoA reacts with the biotin 
analog biocytin1 to form acetyl-CoA, and has no activity in the absence of biocytin (Figure 3.2 
B, Black) [11].  In the presence of full-length BCCP (Figure 3.2 B, Stripes), there is also no 
activity, indicating that BCCP cannot be used as a substrate, which is consistent with previous 
reports [2]. In contrast, when BD is used as a substrate (Figure 3.2 B, Dots), the activity 
increases dramatically, consistent with previous findings [9].  When reconstituted BCCP is used 
as a substrate (Figure 3.2 B Squares), the activity is zero.  Thus, just like with the BC subunit, 
when BCCP was reconstituted the effect on catalysis is similar to the effect of full-length BCCP. 
Therefore, the data from Figure 3.2 demonstrate that NTD acts as a negative regulator of both 
half-reactions. 
            The effect of NTD on the overall reaction catalyzed by ACC (Scheme 3.1) is shown in 
Figure 3.3.  For the assays in Figure 3.3, the activity of ACC is determined by measuring the 
production of ADP from the hydrolysis of ATP in the first half-reaction.  In Figure 3.3 (Black), 
the activity of ACC using full-length BCCP was measured and set to 100%.  When the activity 
of the overall reaction was measured using BD instead of full-length BCCP, there was an 87% 
decrease in activity (Figure 3.3, Stripes).   When NTD was added (i.e. reconstituted BCCP) 
activity was restored (Figure 3.3, Dots).  Thus, in contrast to the negative effect on the isolated 
half-reactions, NTD appears to have a positive effect in the overall reaction catalyzed by ACC.    
                                                
1 Biocytin is biotin with lysine attached to the valeric acid side chain. Biocytin is used in lieu of 
biotin because the Vmax is 3 fold higher compared to using biotin as a substrate [11] 
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A.                             
 
BCCP  +   
BD   + + 
NTD    + 
 
B.          
 
BCCP  +   
BD   + + 
NTD    + 
Figure 3.2. The Effect of NTD on the Enzymatic Activity of the Half-Reactions.  A. Effect of 
NTD on the half-reaction catalyzed by BC. All reactions were run with 8 µM BC in 10 mM 
HEPES (pH 7.8) 150 mM KCl and 0.4 mM ATP. From left to right, the first reaction (     ) 
represents the ATPase activity of BC. This was used as a control and set to 100%.  The second 
reaction represents ATPase activity of BC in the presence of 50 µM full-length BCCP. The third 
reaction (     ) represents the ATPase activity of BC in the presence of 50 µM BD. The fourth 
reaction (     ) represents ATPase activity of BC in the presence of reconstituted BCCP (50 µM of 
the BD and 50 µM of NTD).  B. Effect of NTD on the half-reaction catalyzed by CT. All 
reactions were run with 6 µM CT in 10 mM HEPES (pH 7.8) and 150 mM KCl and 0.15 mM 
malonyl-CoA. From left to right, the first reaction represents the activity of CT in the absence of 
NTD. The second reaction represents the activity of CT in the presence of 50 µM full-length 
BCCP.  The third reaction (     ) represents the activity of CT in the presence of 50 µM BD. The 
fourth reaction represents the activity of CT in the presence of reconstituted BCCP (50 µM of the 
BD and 50 µM of NTD).  A (+) symbol below the bar indicates the presence of either BCCP, 
BD, NTD or a combination of the aforementioned proteins. Each measurement represents the 
average of three replicates ± the standard deviation. 
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BCCP +   
BD  + + 
NTD   + 
Figure 3.3. Effect of NTD on the Hydrolysis of ATP in the Overall ACC Reaction. All reactions 
contained 8 µM BC, 6 µM CT, in 10 mM HEPES (pH 7.8) and 150 mM KCl, 0.4mM ATP, and 
0.15 mM acetyl-CoA.  From left to right, the first reaction (     ) represents the activity of ACC in 
the presence of 50 µM full-length BCCP.  This was used as a control and set to 100%.  The 
second reaction (    ) represents the activity of ACC in the presence of 50 µM BD. The third 
reaction (    ) represents the activity of ACC in the presence of reconstituted BCCP (50 µM of the 
BD and 50 µM of NTD).  A (+) symbol below the bar indicates the presence of either BCCP, 
BD, NTD or a combination of the aforementioned proteins.  Each measurement represents the 
average of three replicates ± the standard deviation. 
To investigate the effect of the NTD on not just ATP hydrolysis (Figure 3.3) but on the 
overall reaction, the production of malonyl-CoA was examined. The enzyme 1,3,6,9 
tetrahydroxynapthalene synthase (THNS) was utilized to measure malonyl-CoA production by 
ACC.  THNS catalyzes the cyclization of malonyl-CoA to form tetrahydroxynapthalene.  Under 
oxidizing conditions, tetrahydroxynapthalene is converted to flaviolin, which absorbs at 340 nm 
[13].  The production of malonyl-CoA by ACC using full-length BCCP was set to 100% (Figure 
3.4, Black). When the BD was substituted for full-length BCCP there was a 45% decrease in 
malonyl-CoA production (Figure 3.4, Stripes).  In contrast, when reconstituted BCCP was used, 
the same amount of malonyl-CoA was produced compared to full-length BCCP, indicating that 
BCCP activity can be reconstituted (Figure 3.4, Dots). It is important to note that the values in 
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Figure 3.3 are based on initial velocities, whereas the values in Figure 3.4 are based on a change 
in absorbance over a 6 hour incubation period, meaning, the two assays can only be compared 
qualitatively. Thus, the results from Figure 3.4 are consistent with the results from Figure 3.3, 
and indicate that NTD markedly increases the effectiveness of the overall ACC reaction.    
 
 
BCCP +   
BD  + + 
NTD   + 
 
Figure 3.4. Effect of NTD on the Production of Malonyl-CoA.  All reactions contained BC, CT, 
ATP, and acetyl-CoA. From left to right, the first reaction (     ) represents the activity of ACC in 
the presence of full-length BCCP.  This was used as a control and set to 100%.  The second 
reaction (     ) represents the activity of ACC in the presence of BD. The third reaction (     ) 
represents the activity of ACC in the presence of reconstituted BCCP.  A (+) symbol below the 
bar indicates the presence of either BCCP, BD, NTD or a combination of the aforementioned 
proteins.  Each measurement represents the average of three replicates ± the standard deviation. 
 
3.3.3 The Effect of NTD on Half-Reaction Kinetics    
            The results from Figure 3.2 show BCCP inhibits activity of both half-reactions of ACC, 
whereas BD acts as a substrate. This indicates NTD is the regulatory moiety of bacterial BCCP. 
Therefore, the mechanism by which NTD inhibits BC and CT activity was investigated using 
dead-end inhibition analyses.  A competitive inhibition pattern was observed when biotin, a 
substrate for BC, was varied at fixed increasing concentrations of NTD (Figure 3.5 A). When 
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data were fitted to equation 1, an inhibition constant (Ki) of 204.0 ± 31.0 µM was determined.  
Consistent with the BC half-reaction, NTD also exhibited a competitive pattern versus biocytin, 
when assaying CT (Figure 3.5 B). When data were fitted to equation 1 an inhibition constant (Ki) 
of 119.8 ± 13.9 µM was calculated.  A competitive inhibition pattern usually indicates the 
inhibitor is binding in place of the substrate in the active site.  If NTD bound in the active site of 
either BC or CT, then it would act as an inhibitor in the overall reaction, thereby preventing 
production of malonyl-CoA. The data from Figure 3.3 and Figure 3.4 refute this conclusion, so it 
is unlikely NTD is binding in the biotin site of either BC or CT.  A possible explanation for the 
competitive inhibition patterns observed in Figure 3.5 is that NTD binds the substrate 
biotin/biocytin, and inhibits activity by substrate depletion.   
            To determine if NTD binds biotin, biotin linked agarose beads were used as a target to 
immobilize purified NTD. After washing to remove any excess NTD, the beads were incubated 
with free biotin to act as a competitor with the biotin attached to the agarose beads. As seen in 
Figure 3.6 A, NTD is present in the eluent, indicating that it does bind biotin.  When full-length 
BCCP was used in place of NTD a similar result was observed (Figure 3.6 B), indicating BCCP 
also binds biotin.  The discovery that the N-terminal domain of BCCP binds biotin explains the 
observation by Choi-Rhee and Cronan [21], that overexpression of the gene coding for NTD 
extragenomically is toxic, because the NTD binding biotin decreases the availability of the 
vitamin. This would prevent biotin protein ligase from biotinylating ACC, thereby decreasing 
activity of ACC, and by inference cell growth. 
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A. 
 
B. 
 
Figure 3.5. Inhibition of the Half-Reactions by NTD. A. Inhibition of the BC half-reaction by 
NTD. All reactions contained 8 µM BC in 10 mM HEPES (pH 7.8) and 150 mM KCl.  Inhibition 
by NTD on the BC half-reaction at 0 µM (l), 50 µM (n), and 100 µM (u) while varying biotin 
and holding ATP constant at 0.4 mM.  The points represent observed velocities, while the lines 
represent best fit of the data to equation 1.  B. Inhibition of the CT half-reaction by NTD. All 
reactions contained 6 µM CT in 10 mM HEPES (pH 7.8) and 150 mM KCl. Inhibition by NTD 
on the CT half-reaction at 0 µM (l), 50 µM (n), and 100 µM (u) while varying biocytin and 
holding malonyl-CoA constant at 0.15 mM.  The points represent observed velocities, while the 
lines represent best fit of the data to equation 1. 
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     A.                                                                     B.  
      
 
Figure 3.6. Pull-Down Assays to Determine if NTD and BCCP Bind Biotin. A. Represents 
biotin agarose beads bound to NTD. B.  Represents biotin agarose beads bound to BCCP. 
 
The pull-down assays support the notion that the inhibition patterns in Figure 3.5 are due 
to NTD binding biotin, inhibiting the reaction by substrate depletion.  Traditionally, enzyme 
inhibition by substrate depletion results in non-linear double-reciprocal plots, however, this only 
occurs when the substrate and inhibitor concentrations are of comparable magnitudes [22]. In 
Figure 3.5 the concentration of biotin is mM, while the concentration of NTD is µM, resulting in 
BCCP 
NTD 
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insignificant depletion of the substrate biotin, which gives a pure competitive inhibition pattern 
[22].    
            There are two possible mechanisms for enzyme inhibition by substrate depletion.  One 
mechanism involves the inhibitor (I) binding the substrate (S) (Scheme 3.2).  
 
Scheme 3.2. 
 
An alternative mechanism occurs when the inhibitor (I) binds the substrate (S) and the inhibitor-
substrate complex (SI) binds to the enzyme (E) competing with free substrate (S) (Scheme 3.3) 
[22]. 
                                                
Scheme 3.3. 
 
            When the activity of the overall reaction is measured where NTD is varied and the 
complex composed of BC, the BD, and CT was held constant, the Km for NTD was 2.85 ± 0.03 
µM.  This is 72-fold and 42-fold lower than the inhibition constants (Ki) for NTD in the half-
reactions catalyzed by BC or CT, respectively.  If the mechanism of inhibition by NTD for the 
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half-reactions occurred as in Scheme 3.3 where the NTD-inhibitor complex binds to either BC or 
CT, the inhibition constant would be expected to be closer to the Km for NTD binding.  The fact 
that the inhibition constants for BC and CT are significantly higher than the Km for NTD binding 
suggests the mechanism of inhibition is Scheme 3.2.       
3.3.4 The Role of NTD in the Catalytic Mechanism 
            One possible physiological role for NTD is to stabilize the carboxybiotin intermediate 
during translocation from BC to CT.  To test this postulate, the BC-BCCP complex was formed 
in vitro and bound to His-tag Dynabeads via a His-tag on their N-termini.  The substrate ATP 
was added and the first half-reaction, in which carboxybiotin is formed (Scheme 3.1), was 
allowed to proceed for 10 min.  The beads were pelleted and washed to remove any unreacted 
ATP.  If the N-terminus protects carboxybiotin, the mixture should contain BC, BCCP, and 
carboxybiotin, which interacts with the N-terminal domain of BCCP.  To transfer the carboxyl 
group from carboxybiotin to acetyl-CoA to form malonyl-CoA, CT and acetyl-CoA were added.  
The amount of malonyl-CoA produced was determined using THNS, which converts malonyl-
CoA into tetrahydroxynapthalene, which under oxidizing conditions forms flaviolin [13]. The 
results are shown in Figure 3.7.  The amount of malonyl-CoA formed using full-length BCCP 
was set to 100% (Figure 3.7, Black).   To evaluate if the NTD stabilizes carboxybiotin, the 
experiment was repeated using BD in place of BCCP. If the NTD does stabilize the 
carboxybiotin, there should be no production of malonyl-CoA in its absence, as the 
carboxybiotin would be quickly decarboxylated. When the BD was used as the source of biotin 
the percent activity was 16% compared to full-length BCCP (Figure 3.7, Stripes).  Though some 
flaviolin, and by inference malonyl-CoA was produced, this small amount may be attributed to a 
small amount of carboxybiotin remaining after the first step of the experiment. Lastly, when 
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reconstituted BCCP was used, malonyl-CoA production was 78% compared to full-length BCCP 
(Figure 3.7, Dots), which indicates that the two domains of BCCP do not need to be covalently 
linked in order to catalyze the reaction.  Thus, the results suggest that in the absence of NTD, the 
carboxybiotin intermediate readily decomposes, and the role of NTD is to stabilize the 
carboxybiotin intermediate.  
 
BCCP +   
BD   + + 
NTD   + 
   
Figure 3.7. The Effect of NTD on the Stabilization of the Carboxybiotin Intermediate.  All 
reactions contained BC, CT, ATP, and acetyl-CoA. From left to right, the first reaction (     ) 
represents malonyl-CoA production using full-length BCCP.  This was used as a control and set 
to 100%.  The second reaction (     ) represents malonyl-CoA production using BD in place of 
full-length BCCP. The third reaction (     ) represents malonyl-CoA production using 
reconstituted BCCP in place of full-length BCCP. A (+) symbol below the bar indicates the 
presence of either BCCP, BD, NTD or a combination of the aforementioned proteins.  Each 
measurement represents the average of three replicates ± the standard deviation. 
 
3.4 Discussion  
3.4.1 The NTD is Unique to Bacterial Acetyl-CoA Carboxylase 
            Most bacterial BCCP contains a domain that is homologous to NTD from E. coli, 
however, this domain does not exist in eukaryotic ACC.  The three-dimensional structure of 
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ACC from yeast gives insight into why the eukaryotic enzyme does not require a domain 
homologous to NTD.  ACC from yeast is a homodimer, where each subunit has domains 
corresponding to the BC and CT proteins found in E. coli, and a domain homologous to the BD 
domain in E. coli BCCP [23]. The three-dimensional structure from yeast contains a channel 
through which the BCCP domain, containing carboxybiotin, translocates during catalysis.  This 
channel is most likely responsible for protecting the carboxybiotin intermediate, thus, eukaryotic 
ACC would not require a domain homologous to NTD.  This begs the question of why the NTD 
in bacterial ACC was conserved throughout evolution.    
3.4.2 The NTD in Bacterial ACC Stabilizes the Carboxybiotin Intermediate.  
            Any proposed function for NTD in bacterial ACC begins with the observation that full-
length BCCP prevents ATP-hydrolysis by isolated BC [2], whereas the BD can be used as a 
substrate for isolated BC [9]. Therefore, in the absence of NTD, the carboxybiotin covalently 
linked to the BD must be undergoing nonproductive decarboxylation after each reaction with 
isolated BC to allow for multiple turnovers.  This observation combined with the findings in this 
study suggest the mechanism by which NTD inhibits ATP hydrolysis in the isolated BC reaction 
is by binding and stabilizing the carboxybiotin, which prevents nonproductive decarboxylation 
and removes biotin as a substrate thereby preventing multiple turnovers. Ultimately, the NTD 
acts as a regulatory moiety of BCCP to prevent ATP hydrolysis by isolated BC. This fact is 
important physiologically because it prevents wasteful hydrolysis of ATP by the BC-BCCP 
complex when the CT subunit and its substrate acetyl-CoA are not available.   
            Protection of the carboxybiotin intermediate has also been observed in the related biotin-
dependent enzyme pyruvate carboxylase [24, 25, 26].  Pyruvate carboxylase has BC and BCCP 
functions similar to ACC as well as a pyruvate carboxylation site that mimics the CT subunit in 
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ACC. These proteins for pyruvate carboxylase form domains on a single polypeptide.  Pyruvate 
carboxylase catalyzes the carboxylation of pyruvate to form oxaloacetate where the allosteric 
activator acetyl-CoA is essential for activity.  As with ACC, the biotin carboxylase and pyruvate 
carboxylation domains communicate.  In the case of pyruvate carboxylase, the communication is 
mediated via acetyl-CoA.  In the absence of acetyl-CoA, the BCCP domain has unrestricted 
movement, which allows the carboxybiotin moiety to be readily decarboxylated by either the 
biotin carboxylase domain or an empty pyruvate carboxylation active site.  In contrast, acetyl-
CoA restricts the BCCP domain movement thereby protecting the carboxybiotin intermediate.  In 
an analogous manner, the NTD of ACC performs the same function.      
3.4.3 The N-terminal Domain of Biotin Carboxyl Carrier Protein is Flexible 
            If the role of NTD is to inhibit decarboxylation of the carboxybiotin intermediate, then 
the domain is likely to exhibit a modicum of flexibility in order to be able to translocate between 
BC and CT.  The first evidence of the flexibility of NTD came from the crystal structure of full-
length BCCP in complex with BC [20]. In this structure, it was found the BD interacted with BC, 
which is consistent with the fact that BD contains the biotin moiety (substrate). There was, 
however, no electron density observed for the N-terminal domain, suggesting the domain is 
highly flexible [20].  
 There is no structural data available for the NTD, despite its small size (8.08 kDa).  
Therefore, BCCP was modeled computationally to gain insight into the three-dimensional 
structure of the N-terminal domain.  The secondary structure prediction for the BCCP sequence 
was carried out with PSIPRED [15].  The results are shown in Figure 3.8 A.  The vertical axis 
indicates the probability, from 0 to 1.0, of the formation of either an α-helix (purple) or a β-sheet 
(yellow), while the horizontal axis corresponds to the residue number in BCCP.  The results 
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indicate residues 3 through 16 form an a-helix, and residues 20-25 and 28-33 form a b-hairpin.  
Additionally, Figure 3.8 A reveals a lack of secondary structural elements in the region between 
residues 35 and 75.  The biotinyl domain starting at residue 79 is composed predominantly of b-
sheets as predicted by PSIPRED.  This is consistent with three-dimensional structures of the 
biotinyl domain [27, 28, 29].    
In order to further support the secondary structure predictions, the probability of disorder 
in the BCCP sequence was predicted using four different programs (Figure 3.8 B).  The vertical 
axis indicates the probability, from 0 to 1.0, of a region being disordered.  All four programs 
consistently assign a high disorder probability to residues 35 through 75, whereas the biotinyl 
domain is clearly structured.  Furthermore, the region of the NTD predicted to form an a-helix 
and a b-hairpin also has a relatively low consensus probability of being disordered, which is in 
agreement with Figure 3.8 A.  Thus, both Figure 3.8 A and B indicate that the N-terminal 
domain of BCCP contains a disordered region.   
Proteins that contain extensive disordered regions are referred to as intrinsically 
disordered proteins or IDPs [30].  An IDP is a protein that lacks a stable three-dimensional 
structure and can vary from being completely without structure, to merely having intrinsically 
disordered regions [30]. Even if an IDP has some ordered regions, these types of proteins are 
extremely difficult to determine three-dimensional structures as they tend to aggregate at high 
concentrations, as is the case for NTD [31].  
Intrinsically disordered proteins can serve several purposes. Protein regions that lack 
stable three-dimensional structures have the ability to interact with multiple partners, because of 
the malleability of the region. This explains why the NTD of BCCP can interact with both the 
BC and CT subunit of ACC, despite the fact that the three-dimensional structures of BC and CT 
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are significantly different [4, 5, 6, 7]. Moreover, intrinsically disordered proteins can aid in the 
transport and binding of small molecules, which is consistent with the hypothesis that the NTD 
stabilizes carboxybiotin.  
 
Figure 3.8. Prediction of Structural Attributes for BCCP. A. The probability of secondary 
structural elements, a-helix and b-strand, estimated by PSIPRED. B. Disorder probability 
reported by DISOPRED, IUPred, disEMBL, and prDOS. 
 
3.5 Conclusions 
There are three significant findings from this report. First, NTD is not required for 
macromolecular complex formation, indicating its major role is catalytic. Second, NTD binds the 
biotin cofactor. Third, NTD stabilizes the carboxybiotin intermediate during catalysis. 
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CHAPTER 4. CONCLUSIONS  
 
4.1 Conclusions and Future Directions 
 
 Acetyl-CoA carboxylase (ACC) is integral to the growth of the cell and therefore a highly 
regulated enzyme [1, 2]. The purpose of this dissertation is to describe two distinct mechanisms 
of regulation of bacterial ACC: feedback inhibition by palmitoyl-acyl carrier protein (PACP), 
and the regulation of catalysis of bacterial ACC by the N-terminal domain of biotin carboxyl 
carrier protein (BCCP).  
 The inhibition of ACC by the downstream product of fatty acid synthesis, PACP, has 
been reported [3], though the mechanism was not determined. The work in this dissertation 
revealed that PACP inhibits ACC in a hysteretic manner. Physiologically, the hysteresis 
exhibited by ACC acts a “surge protector” to mitigate inhibition of the enzyme when the 
concentration of PACP rapidly fluctuates. Alternatively, if PACP remains at a high concentration 
for a prolonged period of time, ACC activity is inhibited, thereby decreasing production of fatty 
acids. PACP was shown to bind to the ACC complex allosterically; however, the exact location 
of binding remains unknown. To determine the binding site, a three-dimensional structure of 
ACC bound to PACP must be determined. 
 One of the most significant findings from this study was the discovery that pantothenic 
acid is the inhibitory moiety of PACP. Though pantothenic acid derivatives are known to have 
anti-malarial activity against Plasmodium falciparum [4] and antibacterial activity against both 
Gram-negative and Gram-positive organisms [5, 6, 7], this is the first report of pantothenic acid 
inhibiting ACC in E. coli. Furthermore, pantothenic acid was shown to inhibit ACC in a time-
dependent manner, and inhibit allosterically, indicating it is binding in a similar location to 
PACP. Thus, pantothenic acid could be used as a scaffold to develop novel antibacterial agents 
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against ACC. Again, for this to occur the three-dimensional structure of ACC in the presence of 
pantothenic acid must be determined. 
 The regulation of ACC by the N-terminal domain in bacterial BCCP is well documented; 
however, the mechanism by which it regulates ACC catalysis had yet to be discovered [8, 9]. 
The work in this dissertation suggests the N-terminal domain is not required for complex 
formation, thus the role of this domain is catalytic. It was also determined that the N-terminal 
domain stabilizes the carboxybiotin intermediate, thereby protecting it during, and possibly 
aiding in, translocation from BC to CT.  The stabilization of the carboxybiotin intermediate by 
the N-terminal domain of BCCP explains the absence of the N-terminal domain in eukaryotes, 
e.g. the fact that the structure of ACC in yeast contains a channel, which most likely protects the 
carboxybiotin moiety, rendering a separate N-terminal domain of BCCP obsolete [10].  
Computational modeling indicates the N-terminal domain is disordered, and therefore 
highly flexible. Intrinsically disordered proteins, such as the N-terminal domain, are capable of 
being involved in a variety of regulatory roles, as these domains are malleable. This explains 
why the N-terminal domain can be involved in regulating both transcription of the accBC operon 
and catalysis by ACC, [8, 9, 11].  The highly flexible nature of N-terminal does not lend itself to 
structural studies; however, the evidence in this study indicates that the N-terminal domain may 
stabilize upon substrates binding to BC. To validate this hypothesis a three-dimensional structure 
of the BC-BCCP complex in the presence of the carboxybiotin analog N1'-methoxycarbonyl 
biotin methyl ester and the product ADP must be determined [12].   
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